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Abstract
Friedreich ataxia (FRDA) is a neurodegenerative disease caused by mutations in the frataxin (FXN) gene,
resulting in reduced expression of the mitochondrial protein frataxin. While there currently is no cure for
FRDA, our increasing understanding of the pathophysiology of disease has led to a surge in the
development of potential treatments. As a result, there is a growing need for biological markers of
disease progression and patient response to therapeutic intervention. In this thesis, we developed and
validated a lateral flow “dipstick” immunoassay for the measurement of frataxin protein in multiple
peripheral cell types. We measured significant differences in frataxin levels between controls, carriers,
and FRDA patients, and found correlations between frataxin levels and GAA1 repeat length and age of onset. We then
compared the utility of the dipstick assay as a population screening and diagnostic tool to a separate, Luminex xMAP-based immunoassay, and discuss
the advantages and disadvantages of each assay in different clinical settings. The dipstick assay showed utility in a variety of clinical applications,
including preliminary diagnosis of atypical FRDA patients, analysis of longitudinal frataxin measurements, correlations with changes in neurological
severity, patient response to HDAC inhibitor treatment, response to chemotherapy in an FRDA case with comorbid osteosarcoma, and assessment of

HDAC and SIRT gene polymorphisms on frataxin protein expression. Finally, we used Stable Isotope Labeling with Essential nutrients in Cell culture
(SILEC) methodology to assess metabolic changes in transfected cells as well as primary fibroblasts and platelets isolated from FRDA patients. Using
SILEC internal standards, we found that acetyl-CoA:succinyl-CoA ratios were significantly decreased in FRDA patients compared to controls, consistent
with in vitro siRNA knockdown models of frataxin. Changes in CoA profiles, coupled with isotopic tracer analysis using [U-13

C6]-glucose and [U-13C

16]-palmitic acid, provided us with further insight into possible metabolic

dysfunction in FRDA. Taken together, the results from this thesis show utility for frataxin measurements from peripheral tissues as a biomarker, and potentially provide researchers with a novel set of markers to assess metabolic dysfunction in unaffected tissues, not just in FRDA, but in any mitochondrial disorder.
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ABSTRACT

MEASURING BIOMARKERS OF FRIEDREICH ATAXIA: IMPLICATIONS FOR
CLINICAL RESEARCH
Eric C. Deutsch
David R. Lynch, MD, PhD

Friedreich ataxia (FRDA) is a neurodegenerative disease caused by mutations in
the frataxin (FXN) gene, resulting in reduced expression of the mitochondrial protein
frataxin. While there currently is no cure for FRDA, our increasing understanding of the
pathophysiology of disease has led to a surge in the development of potential treatments.
As a result, there is a growing need for biological markers of disease progression and
patient response to therapeutic intervention. In this thesis, we developed and validated a
lateral flow “dipstick” immunoassay for the measurement of frataxin protein in multiple
peripheral cell types. We measured significant differences in frataxin levels between
controls, carriers, and FRDA patients, and found correlations between frataxin levels
and GAA1 repeat length and age of onset. We then compared the utility of the dipstick
assay as a population screening and diagnostic tool to a separate, Luminex xMAP-based
immunoassay, and discuss the advantages and disadvantages of each assay in different
vi

clinical settings. The dipstick assay showed utility in a variety of clinical applications,
including preliminary diagnosis of atypical FRDA patients, analysis of longitudinal
frataxin measurements, correlations with changes in neurological severity, patient
response to HDAC inhibitor treatment, response to chemotherapy in an FRDA case with
comorbid osteosarcoma, and assessment of HDAC and SIRT gene polymorphisms on
frataxin protein expression. Finally, we used Stable Isotope Labeling with Essential
nutrients in Cell culture (SILEC) methodology to assess metabolic changes in
transfected cells as well as primary fibroblasts and platelets isolated from FRDA
patients. Using SILEC internal standards, we found that acetyl-CoA:succinyl-CoA ratios
were significantly decreased in FRDA patients compared to controls, consistent with in
vitro siRNA knockdown models of frataxin. Changes in CoA profiles, coupled with
isotopic tracer analysis using [U-13C6]-glucose and [U-13C16]-palmitic acid, provided us
with further insight into possible metabolic dysfunction in FRDA. Taken together, the
results from this thesis show utility for frataxin measurements from peripheral tissues as
a biomarker, and potentially provide researchers with a novel set of markers to assess
metabolic dysfunction in unaffected tissues, not just in FRDA, but in any mitochondrial
disorder.
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Chapter 1: Introduction to Friedreich ataxia and biomarker studies
1.1 Friedreich ataxia: Pathogenesis and genetics
Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder
caused by mutations in the frataxin (FXN) gene resulting in decreased levels of the
mitochondrial protein frataxin. FRDA has a prevalence of approximately 1:40,0001:50,000 people of Western European descent, making FRDA the most common
inherited ataxia.111,114 FRDA was named after German physician Nikolaus Friedreich,
who first reported the condition and its clinical and pathologic features in a series of
patients during the 1860s and 1870s.70-73 FRDA typically presents before the age of 15,
and is characterized by progressive limb and gait ataxia, sensory and proprioception loss,
absent tendon reflexes, dysarthria, and ultimately loss of ambulation 10-15 years after
onset of disease.60,82,151 In addition, many patients may present with progressive scoliosis,
diabetes mellitus, foot deformity (pes cavus), pyramidal weakness, and optic atrophy.60,82
Approximately 50-75% of FRDA patients develop cardiomyopathy or associated cardiac
symptoms which contribute to premature death.82,206 Cognitive function was long thought
to be preserved, but recent studies have suggested deficits in executive function and
motor cognition from cerebellar impairment.46,119,140 Late-onset Friedreich ataxia (LOFA)
is a subdivision of FRDA named for individuals first presenting with signs and symptoms
after the age of 25, and is a result of a variation in disease-causing mutations discussed
below.
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Symptoms of FRDA are indicative of impaired proprioception; neurons involved
in proprioceptive pathways express frataxin normally and show selective degeneration in
FRDA.96,102 Proprioceptive sensory input from Golgi tendon organs and muscle spindles
in skeletal muscle of lower extremities is transmitted rostrally by primary sensory axons
with cell bodies in the dorsal root ganglia (DRG). Conscious proprioceptive input from
the DRG projects to the posterior columns through the medulla and thalamus to the
primary sensory cortex. Unconscious proprioceptive input from DRG afferents synapse
on cell bodies in Clarke’s nucleus of the spinal cord, the major relay center for
unconscious proprioception; axons from Clarke’s nucleus then project to the cerebellar
cortex as mossy fibers. The pathologic hallmark of FRDA is selective degeneration of the
posterior columns in the spinal cord, where axons of DRG sensory neurons are located.
Early loss of large sensory neurons in the DRG is associated with deterioration of
posterior columns, spinocerebellar and corticospinal tracts of the spinal cord, and the
dentate nucleus in the cerebellum.102,136 Large diameter sensory neurons in the DRGs,
which transmit proprioceptive information to the brain, selectively atrophy early in the
time-course of disease, resulting in loss of posterior columns in the spinal cord.97,102 The
sensory neuropathy in this region leads to the loss of vibration and position sense in
FRDA patients that makes up the basis of their ataxia. Neuronal degeneration continues
from large primary sensory neurons to Clarke’s nucleus which results in atrophy of
spinocerebellar tracts relaying signals to the dentate nucleus in the cerebellum.
Degeneration of afferent sensory inputs leads to the atrophy of the dentate nucleus. While
much of the rest of the cerebellum is spared, recent imaging studies suggest cerebellar
2

damage may be more extensive than previously believed, though degeneration of white
matter tracts and the cerebellar peduncles may simply be axon degeneration of dentate
neurons.5,148,166 Progressive degeneration of distal corticospinal motor tracts is a late
phenomenon, suggestive of a dying-back process, and leads to muscle weakness and
extensor plantar responses.137,174 In contrast, scoliosis and absent sensory conduction
action potentials are among the earliest signs of disease, and X-rays show thinning of the
spinal column at first presentation, suggesting subclinical neurological deficits may exist
long before presentation of symptoms and may be a result of early, nonprogressive loss
of sensory neurons.82,125,179
The heart and pancreas are also affected in many FRDA patients. Cardiac
dysfunction often involves hypertrophic cardiomyopathy, including increased lateral
ventricular and intraventricular septum thickness, and arrhythmias.130 While these signs
of heart disease may be asymptomatic and do not correlate well with severity of ataxia,
complications of cardiomyopathy are the leading contributors to early mortality.130,206
Increased iron deposits in cardiomyocytes potentially lead to iron-induced mitochondrial
oxidative damage followed by tissue necrosis.131,171 Heart failure with dilated
cardiomyopathy was seen in deceased patients, representing end-stage progression of
cardiac dysfunction.206 Approximately 10% of FRDA patients develop diabetes mellitus,
and 20% have glucose intolerance. Diabetes in FRDA is complex and shares features
with both Type I and Type II diabetes including autoimmune-independent destruction of
pancreas islet cells, diabetic ketoacidosis, and peripheral insulin resistance.80,82,100,165,184
Frataxin may contribute to oxidative stress and insulin release in response to glucose, as
3

frataxin expression in pancreatic islets from non-FRDA type II diabetes patients is much
lower than control islets without type II diabetes, and correlates with glucose stimulation
and nitrotyrosine.54
Though the signs and symptoms of FRDA had been well-characterized since
Friedreich’s initial reports, more than 125 years passed before the FXN gene (originally
named X25) and the disease causing mutations were finally identified and mapped to
chromosome 9q13.32 The majority (96-98%) of patients are homozygous for GAA
trinucleotide repeat expansions of ~40-1700 repeats within the first intron of the FXN
gene, with the repeat length on the shorter allele directly correlating with age of onset and
disease severity.32,91,142,185 The rest of FRDA patients are compound heterozygotes with a
GAA expansion on one allele and a point mutation or deletion on the other; these patients
may exhibit atypical signs and symptoms of FRDA.47 Normal alleles contain fewer than
40 repeats, though studies show a bimodal distribution of normal alleles; “small normal”
alleles contain between six and 12 repeats, and “large normal” alleles contain between 13
and 34 repeats.48,135 Normal alleles with >34 repeats exist, and are more prone to
hyperexpansion upon transmission to the next generation, suggesting meiotic
instability.48,135 Long GAA expansions are also unstable, leading to somatic mosaicism
even within a single cell.17,50,51,134
GAA triplet repeat expansions lead to decreased FXN transcription, resulting in
reduced levels of frataxin protein.32 This inhibition may be the result of formation of
sticky or triplex DNA structures through self-association of long, uninterrupted stretches
of GAA repeats preventing transcription elongation by RNA polymerase.175-177 In
4

addition, the formation of heterochromatin through reduced H3 and H4 acetylation and
increased H3K9 methylation has been observed.6,34,87,101 Therefore, therapeutic strategies
aimed to rescue frataxin levels through reversal of formation of complex DNA structures
heterochromatin formation have emerged (see Chapter 1.3).
1.2 Role of Frataxin protein
Human frataxin is a highly conserved, 210 amino acid (~17 kDa) protein encoded
in the nucleus with an N-terminal mitochondrial targeting sequenced removed during a
two-step maturation process.16,60,183 Human frataxin is initially cleaved by mitochondrial
processing peptidase (MPP) between G41 and L42, removing the N-terminal
mitochondrial targeting sequence.104 The location of the second cleavage site has been
debated, but was recently shown to occur between K80 and S81, resulting in a 14.3 kDa
mature protein (m81-FXN); a second mature form, cleaved between A55 and S56 (m56FXN), may occur in vitro or if the m81-FXN cleavage site is unavailable.40,183 GAA triplet
repeat expansions in the first intron of the FXN gene result in impairment of FXN
transcription instead of alteration of frataxin protein, which reduces levels of frataxin
protein to 5-30% of normal.31 As a result, FRDA is a disease of frataxin deficiency, not
of the complete absence of frataxin protein, as frataxin knockout mice are embryonic
lethal.49 Frataxin is ubiquitously, but differentially, expressed in all mitochondriacontaining cell types, with expression being highest in metabolically demanding tissues
of the spinal cord and heart, and intermediate in liver, skeletal muscle, cerebellum and
pancreas.96,103

5

The exact function of frataxin remains unclear, but it is now understood that
frataxin plays a major role in mitochondrial iron metabolism including iron binding, iron
storage, iron-sulfur cluster (ISC) biosynthesis, and potential defense against reactive
oxygen species (ROS).11,36,68,74,75 Reduced levels of frataxin results in decreased ISC
biosynthesis, increased sensitivity to oxidative stress and increased mitochondrial iron
(Figure 1).22,167,213 Studies in mouse and yeast models as well as in FRDA patient-derived
cells have shown a deficiency in ISCs, implying a direct role for frataxin in biogenesis or
assembly of ISCs.37,167,168 The interaction between frataxin and ISC biosynthesis is now
well-characterized; frataxin enhances ISC assembly by acting as an iron chaperone to
deliver iron to the ISCU/Nsf1 scaffolding complex, which in turn facilitates production of
ISCs in an iron-dependent manner.3,42,59,106,152,167,188,205,210,218 ISCs are composed of iron
and sulfur atoms that function as prosthetic groups for many different mitochondrial
enzymes, including aconitase in the citric acid cycle and complexes I-III of the electron
transport chain (ETC).15,168 Frataxin also serves as the iron chaperone that delivers iron to
ferrochelatase, the enzyme responsible for catalyzing the final step in heme
synthesis,85,217 and as the chaperone involved in protecting the ISC-containing enzyme
aconitase from [4Fe-4S]2+ disassembly to the inactive [3Fe-4S]1+ core, a marker for
protein oxidation in oxidative stress.25 Frataxin is believed to supply inactive aconitase
with iron to reactivate the damaged ISC core.26,27 In addition, frataxin interacts with
complex II of the ETC, suggesting a more direct role in mitochondrial energy
production.79 Decreased ISC biosynthesis causes reduced activity of ISC-containing
enzymes, including complexes I-III and aconitase, resulting in decreased energy
6

metabolism. As a result, impaired electron flow through the ETC causes increased
leakage of electrons from the respiratory chain. These electrons directly react with
molecular oxygen to form superoxide (O2-), which is converted to hydrogen peroxide
(H2O2) by superoxide dismutase. Reduced frataxin protein also leads to an increase in
intramitochondrial iron levels without changing serum iron levels, increasing the amount
of highly reactive Fe(II) that cannot be managed.157,214 This increased free mitochondrial
ferrous iron reacts with H2O2 to produce damaging hydroxyl radicals in the Fenton
reaction:4

This results in frataxin-deficient cells from FRDA models being highly sensitive
to oxidants.10,90,215 With less iron used for ISC synthesis, more Fe(II) is available to react
with H2O2 for generation of toxic hydroxyl radicals, leading to ISC inactivation, lipid
peroxidation, and protein, nucleic acid oxidation, and mitochondrial damage followed by
eventual cell death.53 ROS-mediated cell death may be the foundation of the progression
of neurological and muscular symptoms, ultimately leading to cardiomyopathy.147 Yeast
and human frataxin both bind ferrous iron, and frataxin multimers are able to sequester
and detoxify excess iron;2,35,41 this may protect the cell against an intramitochondrial iron
overload, controlling the formation of highly reactive oxygen species through Fenton
chemistry.30,75,99,144 Normal levels of frataxin protect DNA and the cell against ironinduced oxidative damage by supplying the mitochondrion with Fe(II) while
simultaneously preventing it from taking part in generation of oxidants.24,75,144
7

Overexpression of frataxin may protect the cell against ROS, while RNAi used to
suppress frataxin expression in a Drosophila model showed that reduced frataxin
enhanced oxidative inactivation of aconitase.109,169 There is evidence that frataxin may
regulate antioxidant defenses that protect cells from oxidants.189 Although the
contribution of each of these events to the pathology seen in the disease and why some
cell types are spared over others remains unknown, it is likely that cell death is a result of
mitochondrial dysfunction from impaired ISC-containing mitochondrial enzymes or
decreased protection against iron-mediated oxidative stress.
1.3 Therapeutic strategies in Friedreich ataxia
There is currently no approved treatment for FRDA in the United States, but
several potential therapies aimed to correct mitochondrial dysfunction in FRDA or
increase expression levels of frataxin are under development. These strategies include use
of antioxidants and coenzyme Q analogs, iron chelators, histone deacetylase inhibitors,
erythropoietin mimetics, and gene therapy. At present, such agents are all in various
stages of evaluation for clinical use (Table 1).
Antioxidants were among the first class of agents investigated to correct
mitochondrial dysfunction in FRDA, as oxidative stress was long believed to be involved
in the pathology of disease. Coenzyme Q10 and vitamin E are common nonprescription
agents used to reduce oxidative stress, though clinical studies show limited cardiac and
neurologic benefit.43,83,110 One of the first drugs used in FRDA clinical trials since the
discovery of the FXN gene was idebenone, a synthetic coenzyme Q10 analog. Like
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coenzyme Q10, idebenone facilitates energy production as a free radical scavenger and as
an electron carrier in the respiratory chain, and may rescue deficiencies in the ETC in
FRDA.128 In 1999, Rustin et al. showed that idebenone not only protected heart
homogenates against iron-induced lipoperoxidation and complex II inactivation, but also
decreased left ventricular mass index in three FRDA patients.171 Several prospective
open-label studies soon followed and confirmed the beneficial effect of idebenone on
cardiomyopathy in FRDA with minimal neurological improvement.29,84,170 Randomized,
placebo-controlled clinical trials have further investigated the long-term effects of
idebenone on cardiac and neurological parameters, with mixed results.56,57,
105,116,121,129,154,163

The 6-month phase III Idebenone effects On Neurological ICARS

Assessments (IONIA) study and a 12-month extension (IONIA-E) study showed modest
neurological improvement based on International Cooperative Ataxia Rating Scale
(ICARS) and Friedreich Ataxia Rating Scale (FARS) scores when taking idebenone
compared to placebo; only the change in ICARS in the IONIA-E study was statistically
significant.116,129 However, no significant differences in cardiac function or left
ventricular hypertrophy were seen between idebenone and placebo groups, suggesting a
lack of benefit of idebenone over a 6-month period for cardiac function.105 Although
idebenone is conditionally approved as treatment for FRDA in Canada, results from the
above studies indicate that idebenone do not meet requirements for FDA approval in the
United States, and there are no clinical trials presently being discussed; however,
idebenone is well-tolerated and non-pharmaceutical grade drug remains available to
FRDA patients as a nutritional supplement through online sources.
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Recently, second generation coenzyme Q10 analogs have been developed and are
undergoing evaluation for the treatment of FRDA. EPI-A0001 (alpha-tocopherolquinone)
is a coenzyme Q10 analog with increased potency developed by Edison Pharmaceuticals
aimed to restore mitochondrial function. A double-blind placebo-controlled phase II
study was just completed evaluating the effect of EPI-A0001 on glucose regulation in
FRDA.117 The primary endpoint of insulin resistance showed no changes with EPI-A0001
compared to placebo, but statistically significant improvements in neurological function
as measured by the FARS were seen in the low and high dose A0001 groups compared to
placebo. The drug was well tolerated in both treatment arms, and additional clinical trials
are in development to further investigate efficacy of EPI-A0001 in FRDA. Edison
Pharmaceuticals has also sponsored an open-label phase II study to investigate EPI-743, a
para-benzoquinone therapeutic with 1,000-10,000-fold more potency than coenzyme
Q10 or idebenone, for the treatment of inherited mitochondrial disorders in 14
individuals, including one patient with FRDA.62,190 While clinical and quality-of-life
parameters were modified and the drug appears to be safe, more clinical trials are needed
to evaluate benefit of EPI-743 in FRDA.62
Intramitochondrial iron accumulation and a consequent increase in oxidative
stress are likely involved in the pathogenesis of FRDA. As a result, iron chelating agents
as a potential therapeutic in FRDA have received considerable attention in recent years.
Current focus is on deferiprone, a chelating agent that crosses plasma and mitochondrial
membranes and acts selectively on labile iron without depleting iron from ISC-containing
enzymes.98,164,194 A pilot study was conducted in nine patients receiving low-dose
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deferiprone for six months and demonstrated a positive effect on reducing brain iron
accumulation as measured by magnetic resonance imaging.18 An open-label single-arm
study investigated the effects of combined idebenone and low-dose deferiprone therapy
on neurological and cardiac parameters over 11 months in twenty patients.207
Electrocardiograph analysis revealed a decrease in left ventricular mass index and
intraventricular septum thickness. Overall ICARS scores indicated stabilization in
neurological dysfunction, although there was a divergence in ICARS subscores. A six
month double-blind, placebo-controlled phase I/II study was recently completed to
evaluate the safety and tolerability of low and high-dose deferiprone in FRDA patients.
The results have not yet been published, but were reported at the 4th International
Friedreich Ataxia Scientific Conference in 2011.8 High-dose deferiprone led to
worsening ataxia in some patients, which improved upon discontinuation of the drug.
Administration of low-dose deferiprone was associated with improvements in left
ventricular mass index, and posture, gait and kinetic function Ataxia Rating Scale
subscores in some patients with mild phenotype. Results of an open-label study
examining the safety and effect on cardiac function of long-term deferiprone therapy
(mean 2.8 ± 0.6 years) were also reported at the 4th International Friedreich Ataxia
Scientific Conference in 2011.113 Seven out of nine patients with cardiac hypertrophy at
baseline showed at least a significant improvement in intraventricular septum thickness,
while the other two showed no significant changes. No patients experienced worsening of
cardiac dysfunction or onset of new cardiac disease. Further clinical studies are needed to
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evaluate the proper dosing regimen for maximizing therapeutic effect without resulting in
further toxicity.
Several different classes of drugs are in various stages of clinical investigation to
assess their effects on frataxin protein levels. Resveratrol, an agent found in the skin of
red grapes, potentially increases frataxin expression and improves mitochondrial function
and the Murdoch Childrens Research Institute/FARA is currently recruiting subjects for
an open label pilot study in Australia. Agonists and coactivators of the peroxisome
proliferator-activated receptor gamma (PPARγ) pathway, used in treatment of diabetes,
have been shown to alleviate oxidative stress and increase frataxin protein and mRNA
levels in FRDA primary fibroblasts by two-fold, indicating a link between PPARγ
coactivators and frataxin deficiency.45,122,123 Pioglitazone, a commercially available
PPARγ agonist that crosses the blood-brain barrier, was proposed as a potential FRDA
treatment in 2006, and a randomized placebo-controlled phase III trial is currently
underway to investigate its efficacy on neurological function of FRDA patients over the
course of two years.180 Frataxin protein levels can also be upregulated in a variety of cell
types by in vivo treatment with interferon gamma, including primary cells from FRDA
patients and DRG neurons from YG8R KIKO FRDA mice.203 Dr. Mark Payne has
developed a transactivator of transcription (TAT) frataxin fusion protein to determine
whether exogenous replacement of depleted frataxin in mitochondria can rescue
phenotype. Initial studies in cultured FRDA fibroblasts and tissue-specific knockout
mouse models show TAT-frataxin improved life span and cardiac function, and suggest
protein replacement therapy may be a viable option for treatment in FRDA.208 Finally,
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recombinant erythropoietin (rhuEPO) has been shown to increase frataxin protein
expression without changing frataxin mRNA levels in primary FRDA fibroblasts and
lymphoctyes through an unknown mechanism, suggesting a posttranscriptional effect of
the drug.1,199 Clinical pilot and dose-response trials with rhuEPO showed a persistent
increase in frataxin protein levels in patient lymphocytes along with a reduction in
markers for oxidative stress and an improvement in neurological function based on
various ataxia rating scales.19,20,138 A phase II trial showed a delayed and sustained
increase in frataxin levels in FRDA peripheral blood mononuclear cells (PBMCs) after
the administration of a single dose of Epoetin alfa without an effect on hematocrit,
though these effects were not reproduced in a randomized placebo-controlled study.120,172
A second phase II trial is planned to assess efficacy of Epoetin alfa on physical
performance of FRDA patients. Currently, EPO mimetics are being developed to isolate
the frataxin-increasing characteristics of the drug from the potentially hazardous
erythropoietic properties, and to improve tissue penetrance and feasibility for oral dosing.
Alleviating the blockade of FXN transcription is another target of interest for
FRDA drug development to potentially increase frataxin levels. A recent study showed
DNA methylation around the GAA expansion correlated with frataxin expression and age
of onset, suggesting a role for the epigenetic profile of FXN as a therapeutic target and a
biomarker treatment response.64 Gene silencing in FRDA was shown to involve
methylation of H3K9 and hypoacetylation at histones H3 and H4, which reversed with a
treatment of HDAC inhibitors.87 Synthetic derivatives of the pimelic diphenylamide class
of HDAC inhibitors from the Herman, et al. 2006 study were evaluated for effect on
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frataxin expression levels, and resulted in increased frataxin mRNA and protein levels in
mouse models and FRDA and carrier primary lymphocytes.38,158,159,216 Long-term
treatment with pimelic o-aminobenzamide compound 109 in the YG8R KIKO FRDA
mouse model increased histone acetylation, frataxin protein expression, and aconitase
enzyme activity in the brain and reduced neuronal pathology of the DRG, suggesting a
role for HDAC inhibitors in improving neurological phenotype.178 Preclinical studies
continue to explore safety and efficacy of a new generation of HDAC inhibitors.
While the treatments discussed here have shown some promise, none conclusively
slow disease progression. As we learn more about the function of frataxin protein,
mechanisms of FRDA pathology, and modifiers of frataxin expression, new potential
therapeutic targets are rapidly emerging. Advancements in drug screening tools and
assessment of outcome measures are needed to keep up with the current pace of drug
development and clinical trials.
1.4 Biomarkers and utility in Friedreich ataxia
As with any disease, there is a great need to measure FRDA disease progression
and drug effects in preclinical and clinical studies. To measure the state of these
biological processes, we use biomarkers. The NIH defines a biomarker as “a
characteristic that is objectively measured and evaluated as an indicator of normal
biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention”. Biomarkers are typically classified as Type 0 (natural history biomarkers),
Type I (markers of drug activity), or Type II (surrogate outcomes), though oftentimes a
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can be considered more than one type.132 While there is no formalized validation process
for the use of biomarkers as surrogate measures, a set of biological, statistical, clinical,
and risk/benefit criteria typically must be met. A valid biomarker should show evidence
as a risk factor for the disease of interest, be consistent with pathophysiology, be involved
with the causal pathway of disease, mirror changes in the prognosis, be correlated with
clinical outcome, and should predict outcome in clinical trials for drugs of multiple
pharmacologic classes.202 In the context of FRDA, affected tissues are clinically
inaccessible, creating the need for surrogate markers from unaffected tissues and cells to
reflect pathology. Researchers typically examine all three types of biomarkers in FRDA
studies, including markers of oxidative stress, cardiac and neurological dysfunction,
changes in gene expression and frataxin protein levels all as differences from unaffected
individuals at baseline, in response to pharmacological treatments, or as surrogates for
patient-important outcomes.
Cardiac dysfunction is the major contributor to premature death in FRDA, but
survival analyses are not feasible as outcome measures in FRDA study populations.130,204
Measures of cardiomyopathy, including left ventricular and intraventricular septum
thickness, ejection fraction, and electrocardiogram parameters, are often used as
surrogates for real, undesired clinical endpoints in natural history and clinical trial
studies, and are the focus of several therapeutic strategies.105,149,161,207 While some
therapies have shown modest improvements in cardiac parameters, it remains unclear
whether these benefits are clinically significant in the context of patient survival. At the
4th International Friedreich Ataxia Scientific Conference, we reported chronic elevations
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in serum cardiac troponin in patients without acute coronary syndrome, suggesting a
potential marker to identify those patients at risk for cardiac dysfunction.181 Further
studies are needed to characterize serum markers of myocardial injury with the hope that
they may provide insight into progression of cardiomyopathy and present researchers
with an opportunity to initiate therapeutic intervention before onset of symptoms.
As we understand more about the pathogenesis of FRDA and enroll more patients
for clinical trials, the need to quantify clinical symptoms and the impact of treatments
becomes more important; unfortunately, affected cell types in FRDA are clinically
inaccessible, so surrogate measures of neurological function and progression are required.
While there is no gold standard to measure disease progression in FRDA, studies have
begun to evaluate various ataxia rating scales for validity and accuracy in assessment of
FRDA. The International Cooperative Ataxia Rating Scale (ICARS) was originally
designed for cerebellar ataxias, but has also found an application in FRDA studies.204 The
ICARS ranges from 1 to 100, and contains subscores for posture and gait disturbances,
kinetic functions, speech disorders, and oculomotor disorders.33 Debate remains whether
the ICARS is a reliable measure of FRDA, and further validity testing is required before
the ICARS can be recommended for clinical trials.33,192 The Friedreich Ataxia Rating
Scale (FARS) was developed as a more appropriate scale for FRDA, and correlates well
with activities of daily living, functional disability, and disease duration.115 The FARS
contains five subscores (bulbar, lower and upper extremities, peripheral portion, and
upright stability) and is scored from 0 to 125, with higher scores representing more
severe disease progression.69 Both the ICARS and FARS are still used to assess disease
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progression, but the FARS has shown greater utility in clinical trial settings, as fewer
patients are required to demonstrate the same effect of an intervention.65 The Scale for
the Assessment and Rating of Ataxia (SARA) is a short-form neurological exam
developed for use in dominantly inherited ataxia, but correlates well with the FARS and
has shown some utility as a compact test for use in FRDA clinical trials.20,28,182,200,211 It
remains unknown whether biological markers exist that can predict disease progression
as measured by any of these rating scales for natural history or clinical trial studies.
At the molecular level, studies have focused on markers of potential consequences
of reduced frataxin as a measure of FRDA pathology or pharmacological response. These
include activities of ISC-containing enzymes, urinary and intracellular markers of
oxidative stress, mitochondrial iron levels, mitochondrial DNA levels, and 31phosphorus
magnetic resonance spectroscopy as a measure of energy production;22,23,61,86,110,153
however, these measures have been ineffective in assessing mitochondrial function from
peripheral tissues in large scale clinical studies. As FRDA is caused by depletion of
frataxin protein, measurement of frataxin itself could potentially be useful to assess
severity of disease. Traditionally, frataxin protein levels were measured through Western
blot or enzyme-linked immunosorbent assay (ELISA) analysis from patient-derived cells,
which is not ideal for rapid quantification in a clinical research setting.19,31 An
electrochemiluminescence assay was developed to quantify frataxin from lymphocytes
and fibroblasts, but the procedure is labor-intensive and untested in cell types collected
noninvasively, and is limited by a narrow working range across different cell types and
tissues.197 This same assay, however, did show correlation of frataxin levels in blood and
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skeletal muscle in seven FRDA patients, endorsing frataxin measurements from an
unaffected tissue as a valid biomarker.139 MitoSciences Inc. (now part of Abcam) has
developed a series of lateral-flow immunoassays to measure protein and enzyme activity
levels, including frataxin, without isolating or purifying mitochondria.212 Initial studies
showed significant differences in frataxin levels between lymphoblastoid cells derived
from a small set of FRDA patients, known carriers, and controls, and provided a
reproducible way to measure frataxin protein levels from a variety of cell and tissue
types, including buccal cells and whole blood.212
Here, we have expanded upon these findings by measuring frataxin protein from
large numbers of controls, known carriers, and FRDA patients in multiple cell types and
correlating frataxin levels with measures of disease severity. In Chapter 2, we present two
different techniques for rapidly measuring frataxin protein in unaffected cell types, and in
Chapter 3 we discuss applications for these methodologies in screening and diagnostic
settings. Finally, in Chapter 4 we examine acyl-CoA profiles in cells isolated from FRDA
patients and uncover a potential set of mitochondrial markers for metabolic
rearrangement from peripheral tissues.
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Figure 1 – The role of frataxin protein within the mitochondrion. Pathways in green
indicate decreased function in FRDA, and pathways in red indicate increased activity in
FRDA (adapted from Pandolfo, Nat Clin Pract Neurol., 4, 86-96 (2008).
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Table 1 – Research pipeline in FRDA. Data gathered from the Friedreich Ataxia
Research Alliance and www.clinicaltrials.gov.
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Chapter 2: Utilization of immunoassays for frataxin protein measurement
2.1 Abstract
While there currently is no cure for FRDA, several potential therapies are in the
treatment pipeline, revealing the need for biological and surrogate markers of disease
progression and response to treatment, including the measurement of frataxin protein
itself. Traditionally, frataxin protein levels could only be measured through Western blot
or ELISA analysis from patient-derived cells, which is not ideal for rapid quantification
in a clinical research setting. In this chapter, we have utilized two separate assays to
measure frataxin from patient samples. We first used a lateral flow immunoassay to
measure frataxin protein levels in controls, known carriers, and FRDA patients in
PBMCs, platelets, whole blood, and buccal cells. Significant differences were seen
between groups in all cell types, and the results of the assay were shown to be
reproducible and contain minimal variability. We also used a previously validated
Luminex xMAP-based immunoassay to quantify frataxin protein levels in dried blood
spots from FRDA patients, carriers, and controls. Significant differences were again seen
between these groups, with cutoff values established for population screening purposes.
ROC curve analyses revealed favorable sensitivity and specificity ratios for both assays.
These assays demonstrate potential diagnostic utility and for measuring baseline frataxin
levels in screening or clinical trial settings.

21

2.2 Introduction
FRDA is caused by mutations in the FXN gene encoding the mitochondrial
protein, frataxin. These mutations result in decreased expression of frataxin, which causes
the clinical manifestations of the disease. Approximately 96% of individuals with FRDA
have homozygous expansions of the GAA trinucleotide repeat in the first intron of the
FXN gene, while the majority of the remaining 4% of FRDA patients have the
trinucleotide expansion on one allele and a point mutation or deletion on the second
allele.32 Traditionally, FRDA has been genetically diagnosed for the presence of the GAA
expansion; however, this test cannot be used to effectively monitor treatment or
efficiently utilized for population screening. An immunoassay measuring frataxin protein
levels from easily accessible peripheral tissues would be ideal for both diagnosis as well
as clinical monitoring in FRDA patients. Frataxin protein was typically measured using
Western blot or ELISA analysis, neither of which is feasible for rapid measurements from
large numbers of samples in clinical research settings. A few studies with small sample sizes
have focused on means to quantify frataxin from patient samples; however, these procedures

typically are untested in many peripheral cell types used in clinical studies, and are
limited by narrow working ranges.139,197,198 With increased knowledge of the
pathophysiology of FRDA and the growing number of clinical trials accompanying it,
there is an increased need for clinically accessible biomarkers that follow disease severity
and patient response to pharmacological intervention.
Recently, Mitosciences (now part of Abcam) developed a lateral flow “dipstick”
immunoassay to measure levels of mitochondrial proteins, including frataxin, without the
22

need for isolating mitochondria (Figure 2.1). This assay is based on the principle of the
sandwich ELISA, and uses two different antibodies directed against the mature form of
frataxin protein. Samples are loaded into the bottom of a 96-well plate, where goldconjugated frataxin antibodies bind to the frataxin protein within the sample. As the
sample wicks up the dipstick, frataxin is immunocaptured onto the nitrocellulose portion
of the dipstick by a second antibody, giving rise to a pink line in the capture zone. The
signal intensity corresponds with the amount of frataxin in the sample and is measured by
a dipstick reader. Initial studies used the assay to show differences in frataxin levels
between lymphoblastoid cells derived from a small set of FRDA patients, carriers, and
controls, and provided a reproducible way to measure frataxin protein levels from a
variety of cell and tissue types, including buccal cells and whole blood.212 However, until
this point, studies measuring frataxin protein in large numbers of whole blood and buccal
cell samples had not been conducted.
Our hypothesis was that an assay for the rapid measurement of frataxin protein
from peripheral tissues could then be used for clinical monitoring as well as screening
and diagnostic testing purposes in large numbers of FRDA patients and their families. In
this chapter, we validate and utilize the lateral flow immunoassay for the measurement of
differences in frataxin levels in multiple peripheral cell types collected by noninvasive
and minimally invasive means from controls, carriers, and FRDA patients. We show
correlations between frataxin levels and classical measures of disease severity, including
GAA1 repeat length and age of onset. We also assess frataxin protein levels in patients
with point mutations and LOFA patients, and discuss their effects on how to design the
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immunoassay as a screening tool. Finally, we collaborate with Dr. Devin Oglesbee at the
Mayo Clinic and use an xMAP-based Luminex immunoassay to measure frataxin protein
from dried blood spot (DBS) samples, and discuss the advantages and disadvantages of
using either immunoassay in different clinical settings.
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2.3 Materials and Methods
2.3.1 Patients
These studies had approval by the International Review Board at all participating
institutions. All subjects provided written informed consent before participating in study
procedures.
Clinical and demographic information, including molecular confirmation of FXN
gene mutations, was provided through an ongoing longitudinal natural history study on
FRDA.69 Samples were collected from a majority of these patients at the University of
Pennsylvania/Children's Hospital of Philadelphia, the University of California at Los
Angeles Medical Center, Emory University, University of Florida, and other patients
referred to physicians practicing at these and other institutions. A series of patients with
other disorders also participated as a “diseased” control to account for referral bias. These
subjects had other ataxia or movement disorders in which FRDA has been ruled out by
clinical and genetic criteria. Carriers and normal healthy volunteers also provided
samples for frataxin analysis (Table 2).
2.3.2 Sample preparation
PBMCs and some platelet samples isolated from FRDA patients and normal
healthy volunteers were separated through differential centrifugation and Ficoll gradients
(GE Healthcare) and were generously provided by Dr. Jean-Emmanuel Sarry and Dr.
Mary Selak for this study.186
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To isolate platelets in lab, blood was collected in 8.5 mL glass acid citrate
dextrose Vacutainer tubes (BD Biosciences) and transferred into 15 mL centrifuge tubes.
Blood was spun at 129 g in a swinging bucket centrifuge for 15 min with no brakes. The
upper platelet rich plasma (PRP) layer was transferred to a fresh tube and spun at 341 g in
a swinging bucket centrifuge for 15 min with no brakes to pellet platelets. Platelet pellets
were resuspended in 1 mL PBS (GIBCO) and stored at -80oC until use.
Whole blood from controls, carriers, and patients was collected in K2 EDTA BD
Vacutainer tubes (REF 367844) and frozen immediately at -80oC until use. Whole blood
protein was extracted by mixing 1 volume of whole blood to 3 volumes of ice cold
extraction buffer A (Abcam/MitoSciences) for 15 min at 4oC. Samples were
microcentrifuged at 16,100 g for 10 min at 4oC, and the supernatant was transferred to a
fresh microcentrifuge tube and stored at -80oC until use. Samples were further diluted
1:10 in ice cold extraction buffer A (Abcam/MitoSciences) for frataxin quantity analysis
before use.
Buccal cells were harvested using MasterAmp Buccal Swab Brushes (Epicentre)
by firmly pressing a brush against the inner cheek and swabbed while twirling for 30
seconds on each cheek. Both brushes were then immersed in the same microcentrifuge
tube containing 500 µL of ice cold extraction buffer A (Abcam/MitoSciences) and
twirled gently in the extraction buffer to dislodge the cells. To extract protein from the
buccal cells, the microcentrifuge tubes were incubated on ice for 20 minutes with
intermittent vortexing, and then microcentrifuged at 16,100 g for 10 min at 4oC, and the
supernatant was transferred to a fresh microcentrifuge tube and stored at -80oC until use.
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Protein concentration was determined using the BCA protein assay according to the
manufacturer’s protocol (Pierce) before frataxin protein quantity analysis.
2.3.3 Lateral flow immunoassay protocol
Frataxin protein quantity dipstick assay kits (Abcam/MitoSciences, MSF31) were
used to measure frataxin levels in PBMCs, platelets, whole blood, and buccal cells
(Figure 2.1). To determine the working range of the lateral flow immunoassay (Figure
A.1), a standard curve was generated using recombinant frataxin protein
(Abcam/MitoSciences). Standard curves using representative control samples were run to
determine appropriate amounts of sample to use within the working range of the assay for
all cell types (Figure A.2). For measurement from buccal cells, PBMCs, and platelets, 5
or 10 µg of total cellular protein in 25 µl of ice cold extraction buffer A
(Abcam/MitoSciences) was mixed with 25 µl 2x blocking buffer B
(Abcam/MitoSciences) and added to individual wells on a 96-well plate with goldconjugated mAb at the bottom of each well. Whole blood was further diluted 1:10 in ice
cold extraction buffer A (Abcam/MitoSciences) from the initial preparation and 25 µl
was mixed with 25 µl 2x blocking buffer (Sigma) before added to individual wells. After
samples were allowed to equilibrate with the antibodies, dipsticks were inserted into the
well and sample was allowed to wick up the membrane, where frataxin was
immunocaptured onto designated capture zones on the dipstick. The dipsticks were
washed in 30 µl of wash buffer C (Abcam/MitoSciences) and allowed to dry before
analysis. Capture zones on developed dipsticks were quantified with a Hamamatsu
immunochromato reader (MS1000 Dipstick reader). Raw mABS results were corrected
27

for protein concentration and normalized to the control goat α-mouse IgG band (internal
positive control), and the data were expressed as percentages of the average controls run
on the same assay.
2.3.4 Luminex xMAP-based immunoassay protocol
For each subject, 50 µl of whole blood was spotted on each circle of Protein Saver
903 Cards (Whatman), and cards were allowed to dry before analysis. Protein was eluted
from dried blood spots, mixed with frataxin antibody-coupled microspheres, and
analyzed for frataxin content using the Luminex 200 analyzer at the Mayo Clinic (Figure
2.2). Calibration of frataxin content was performed using purified human frataxin
(courtesy of Dr. Grazia Isaya at the Mayo Clinic).
2.3.5 SDS-Page and western blot analysis
After the protein concentration of samples was determined through a BCA assay
(Pierce), samples were run on 14% acrylamide gels at 120 V for 2 hours and transferred
onto 0.45 µM nitrocellulose membranes at 100 V for 1 hour (Bio-Rad). Blots were
blocked in 3% milk in TBSt for 1 hour, incubated at 4oC in primary antibody overnight
(1:2000 α-frataxin: Abcam/MitoSciences, 1:4000 α-actin: Sigma), and then in secondary
antibody for 1 hour (α-rabbit, α-mouse 1:2000, Cell Signaling). Blots were incubated in
Supersignal West Dura Chemiluminescent Substrate (Thermo Scientific) for 1-2 min and
exposed to Hyblot CL film (Denville Scientific). Protein levels were quantitated by
scanning densiometry analysis using NIH ImageJ software.
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2.3.6 Statistical analysis
Data analysis was performed using STATA SE 11 software and MS Office Excel
2007. Frataxin levels in patient samples were expressed as percentage of average control
for that assay. Student’s t-test was used to compare means in PBMCs, and one-way
ANOVA followed by Scheffe’s post hoc analysis was used to compare means in
platelets, whole blood, and buccal cells. All frataxin levels as measured by dipstick
assays were expressed as a percentage of average controls, and frataxin levels measured
by Luminex assay were expressed as ng/mL whole blood. Simple and multiple regression
analysis were conducted to analyze relationships between frataxin levels and multiple
independent variables.
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2.4 Results
2.4.1 Lateral flow immunoassays distinguish frataxin protein levels between controls,
known carriers, and FRDA samples across multiple cell types
Platelets and peripheral blood mononuclear cells (PBMCs) represent extractable
cell types rich in mitochondrial that may potentially be useful for frataxin measurement
from FRDA patients. As part of a collaborative study with Jean-Emmanuel Sarry and
Mary Selak to assess subclinical abnormalities in unaffected cells, we measured frataxin
protein levels from isolated platelets and PBMCs using the lateral flow immunoassay.186
We did not have sufficient PBMCs to run a proper standard curve, so we chose to load 5
µg of each sample per well, which is in the middle of the working range suggested by
MitoSciences.212 We measured significant differences in frataxin levels between control
and FRDA PBMCs (p < 0.001), with mean FRDA PBMC frataxin levels at 37.6% of
average controls (Figure 2.3A). A standard curve using platelets isolated from a
representative control showed that the dipstick assay remained in the linear range through
20 µg of platelet protein (Figure A.2). Based on this result, we loaded 10 µg of platelet
protein to ensure we conserved platelet samples and were in the center of the working
range for platelets and recombinant frataxin. Typical control platelets contained
approximately 15 pg frataxin/µg total protein based on calculations from the recombinant
frataxin standard curve (Figure A.1). We found significant differences between control
and FRDA platelets (p < 0.001), with mean FRDA platelet frataxin levels equal to 38.1%
of average controls (Figure 2.3B). In addition, we measured frataxin levels in platelets
isolated from three carriers; while the average frataxin level from these samples was in
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between controls and carriers (59.6%), the difference was not statistically significant
because of the small sample size. Clinical information was not obtained for these
samples, so we were unable to correlate frataxin protein levels with other disease
parameters.
While we see clear differences in frataxin levels between controls and FRDA
patients in cells isolated from whole blood, isolation and storage of platelets and PBMCs
for frataxin measurement is difficult in large settings where numerous samples are being
collected. We eliminated the isolation step and measured frataxin levels directly from
whole blood. Based on the results of a standard curve (Figure A.2), we loaded the
equivalent of 2.5 µl of whole blood per well (25 µl diluted 1:10), which was in the
middle of the working range of the assay for whole blood and recombinant frataxin. This
corresponded to approximately 65 pg frataxin/µl whole blood for control samples, based
on the recombinant frataxin standard curve (Figure A.1). We measured frataxin protein
levels in whole blood drawn from large numbers of controls (n=68), known carriers
(n=107), and FRDA patients (n=242), which were divided into LOFA (n=28), point
mutation (PM, n=4), and the remaining FRDA patients (n=207). FRDA patients in this
cohort covered a wide spectrum of FRDA disease severity (Table A.1). Frataxin protein
was significantly reduced in carriers (69.1% of control, p < 0.001) and FRDA patients
(26.4% of control, p < 0.001), with significant decreases also seen in LOFA and PM
FRDA patients (Figure 2.4). While there is some overlap between controls, carriers, and
FRDA patients suggestive of variability between individuals, none of the 95% confidence
intervals or interquartile ranges between groups overlap (Figure 2.4). The increased
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frataxin levels in LOFA patients (54.6% of control) suggest a relationship between age of
onset and frataxin protein levels. In addition to strong correlations between age of onset
and GAA1 repeat length (R2 = 0.665, p < 0.001), we found strong correlations between
age of onset and frataxin (R2 = 0.407, p < 0.001) and GAA1 and frataxin (R2 = 0.415, p <
0.001), suggesting frataxin measurements from whole blood correlate with measures of
disease severity (Figure 2.5). We then performed ROC analysis by measured frataxin
levels in whole blood to assess how well the dipstick assay could correctly identify a
sample as having “disease” or “no disease”. We constructed these curves in two different
ways to ask whether we wanted to test to identify FRDA patients from controls and
carriers, or have the test identify both carriers and FRDA patients together separated from
controls. Both analyses performed very well, with an area under the curve greater than
0.955 for each potential screening method (Figure 2.6A,B). Based on these ROC curves
and mean frataxin levels measured in our samples, we established a set of classification
criteria for the dipstick assay to label an unknown sample as “control”, “carrier/potential
FRDA”, or “FRDA”; we used frataxin levels of greater than 85% of control as our
“control” classifier, 45-85% of control as our “carrier/potential FRDA” classifier, and
<45% of control as our “FRDA” classifier. We then used these classifiers to determine
which screening method was most accurate and clinically useful (Figure 2.6C).
Screening to identify carriers and FRDA patients yielded the highest sensitivity (0.936)
and very high positive predictive value (PPV, 0.967) out of our two screening methods,
indicating that identifying both carriers and FRDA patients from the test will result in the
fewest false negatives (Table A.2). The negative predictive value (NPV) was low (0.722),
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due to the relatively low number of control samples assayed compared to carriers and
FRDA patients. Taken together, these results suggest that using the dipstick assay to
identify patients and carriers based on frataxin levels in whole blood may be a valid
complimentary tool for population screening or diagnosis in large numbers of individuals.
While collection of whole blood is relatively convenient in a clinical setting,
protein extraction from cheek swab samples represents a true, noninvasive sampling
technique that can be utilized in any setting, which may be important for multicenter
clinical studies or visits at patients’ homes. Here, we examined the potential utility of
measuring frataxin protein from buccal cell extracts using the lateral flow immunoassay.
The assay remained in the linear range through 20 µg of buccal cell protein (Figure A.3),
but we decided to use 10 µg based on the amount of protein we could conceivably extract
from a typical cheek swab sample and load in a 25 µl volume. Based on our recombinant
frataxin standard curve (Figure A.1), typical control buccal cell extracts contained
approximately 10 pg frataxin/µg total cheek swab protein. Similarly to whole blood, we
collected buccal cell extracts from a large number of controls (n=90), known carriers
(n=245), and FRDA patients which were broken up into LOFA (n=23), point mutation
(PM, n=11), and the remaining FRDA patients (n=271). These patients also encompassed
a large spectrum of FRDA disease severity as evidenced by the wide range in age of
onset and GAA1/GAA2 repeat length (Table A.3). We measured significant decreases in
frataxin levels in buccal cells from known carriers (58.5% of control, p < 0.001) and
FRDA patients (20.1% of control, p < 0.001); in addition, we also measured frataxin
from a group of non-FRDA patients with other movements disorders (MD) as another
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control group (n=19), and found no significant changes in frataxin compared to
unaffected controls (110.0% of control, p = 0.332), confirming that reductions in frataxin
protein are associated with FRDA (Figure 2.7). We see overlap between control, carrier,
and FRDA patient frataxin protein levels in buccal cells, but note that the interquartile
ranges and 95% confidence intervals between each group do not overlap. We separated
out the LOFA patients and found that LOFA frataxin levels in buccal cells (41.4% of
control) were significantly higher compared to normal FRDA or PM FRDA patient levels
(p < 0.001). Excluding a patient with an R165C mutation, buccal cell frataxin levels from
FRDA patients with missense mutations correlated with GAA2 repeat length (R2 = 0.578,
p = 0.011) and were not statistically different than those from classic FRDA patients. In
spite of the severe phenotype, the elevated frataxin levels in our R165C patients is in
agreement with reports of R165P patients presenting with increased frataxin protein and
mRNA, suggesting that location of a missense mutation may contribute to severity of
disease.173 As expected, we found a strong correlation between age of onset and GAA1
repeat length in the total FRDA population (Figure 2.8A, R2 = 0.620, p < 0.001). Frataxin
levels also showed modest correlations with age of onset (Figure 2.8B, R2 = 0.229, p <
0.001) and GAA1 repeat length (Figure 2.8C, R2 = 0.240, p < 0.001). We carried out two
ROC curve analyses to plot sensitivities and specificities of measured frataxin levels in
buccal cells as previously described in whole blood. Both analyses again performed well,
with an area under the curve greater than 0.930 for each potential screening method
(Figure 2.9A,B). Using the ROC curves and frataxin levels measured in cheek swab
samples, another set of classification criteria was created for the dipstick assay to label an
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unknown cheek swab sample as “control”, “carrier/potential FRDA”, or “FRDA”; here,
frataxin levels of greater than 80% of control was our “control” classifier, 40-80% of
control was our “carrier/potential FRDA” classifier, and <40% of control was our
“FRDA” classifier. We then used these classifiers to construct 2x2 tables to calculate
which screening method was most accurate and clinically useful based on the above
criteria (Figure 2.9C). As with whole blood, the PPV (0.960) and sensitivity (0.918) were
highest when screening for FRDA patients and carriers in cheek swab samples, with a
relatively low NPV (0.662) from a small control population (Table A.4). These values are
comparable to those from whole blood; thus, measuring frataxin protein from cheek swab
samples to identify carriers and FRDA patients may be a viable screening tool in large
clinical settings.
We investigated the reliability and validity of the dipstick assay by measuring
recovery of recombinant frataxin and assessing the variation inherent to the assay itself.
In both whole blood and cheek swab samples, approximately 95% or greater recovery of
up to 100 pg recombinant frataxin was achieved, demonstrating that no other components
of the samples significantly interfered or enhanced the measured frataxin absorbance
(Table A.5). Reproducibility of the lateral flow immunoassay was evaluated by
determining intra-assay, inter-assay, and inter-sample variation within the working range
of cheek swabs and whole blood collected from a representative control (Table A.6). The
dipstick assay was reproducible within the working range with low mean intra-assay
(<6%), inter-assay (<8%), and inter-sample (3.2% and 7.3%, whole blood and cheek
swab, respectively) coefficient of variation (CV) values. CV values were higher in cheek
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swab samples than whole blood; however, the standard deviations were similar in
magnitude between cheek swabs and whole blood, but mean cheek swab frataxin mABS
were lower, i.e. small changes in absolute values result in larger percent CV changes. We
compared frataxin levels from current control whole blood and cheek swab samples to
those collected from the sample individual within the previous four years (Table A.7).
While all samples showed small intra-assay variation, the cheek swab sample mABS
values varied from year to year and were all significantly different from the current cheek
swab sample frataxin levels. In contrast, whole blood samples were all similar to each
other, with no significant differences found.
Taken together, these data suggest that the dipstick assay can measure differences
in frataxin values between controls, known carriers, and FRDA patients in multiple
peripheral cell types. When used to identify carrier and FRDA patient samples from a
population, the assay exhibited a low rate of false negatives and a high PPV and, thus,
may be a useful tool for population screening and diagnosis. There is high recovery and
low variation associated with the assay; however, whole blood samples may be better
suited for long-term storage and analysis compared to cheek swab samples.
2.4.2 The quantitative Luminex xMAP-based assay shows utility as a screening and
diagnostic tool
In collaboration with Dr. Devin Oglesbee at the Mayo Clinic, we also measured
frataxin protein from DBS eluates using the Luminex xMAP-based immunoassay for
potential use as a screening tool (Figure 2.2). At the 4th International Friedreich Ataxia
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Scientific Conference in 2011, Dr. Oglesbee presented clinical validation of the Luminex
immunoassay for measuring frataxin levels in DBS, including recovery, reproducibility,
and stability data pertaining to DBS storage.141 To determine how applicable the
Luminex immunoassay is for population screening compared to the dipstick assays, we
measured frataxin protein via Luminex assay in 23 controls, 76 carriers, and 141 FRDA
patients (Table A.8). Age of onset correlated strongly with GAA1 (R2 = 0.713, p < 0.001)
in these patients, as did frataxin levels (R2 = 0.568, p < 0.001) as measured by Luminex
assay in DBS (Figure 2.10A,B). Of those individuals, we measured frataxin levels in
parallel via dipstick assay in 17 controls, 54 carriers, and 90 FRDA patients (Table A.8).
Frataxin levels measured by Luminex assay correlated strongly with frataxin levels as
measured by dipstick assay (R2 = 0.742, p < 0.001, Figure 2.10C), demonstrating
reproducibility of frataxin measurements across multiple assays.
As seen in Chapter 2.4.1, we measured reduced frataxin levels in carriers (mean
70.6% of control) and FRDA patients (mean 35.7% of control) using the dipstick assay
(Figure 2.11A). Reduced frataxin levels were also seen in carriers (15.2 ng/mL) and
FRDA patients (6.9 ng/mL) relative to controls (28.5 ng/mL) as measured by the
Luminex assay (Figure 2.11B); frataxin levels were quantified by comparing
fluorescence intensity to a standard curve using purified human frataxin. Differences in
frataxin levels between controls, carriers, and FRDA patients in both assays were
statistically significant (p < 0.001).
To determine how well the Luminex assay performs as a population screening
tool, we conducted two separate ROC analyses on the measured frataxin values to
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determine which individuals we wanted to identify from our test, and compared the
results to values from dipstick assay measurements (Figure 2.12A-D). In each
circumstance for both assays, the area under the ROC curve was greater than 0.915,
signifying that each may be an accurate and potentially worthwhile test. The area under
the curve was higher for the dipstick assay than the Luminex assay, although fewer
samples were analyzed by dipstick analysis. Based on the shape of the ROC curves and
mean values from our frataxin measurements, we chose specific frataxin levels as cutoff
points for both assays to classify each sample as a “control”, “carrier/potential FRDA
patient”, or “FRDA patient”. Using these classification criteria, we created 2x2 tables to
examine the operating characteristics and predictive value of each assay for each question
we wanted our screening tool to answer (Figure 2.13A,B). Confirming our findings in
Chapter 2.4.1, screening for FRDA patients and carriers versus unaffected controls
offered the highest or close to the highest sensitivities and PPVs in both the dipstick and
Luminex assays (Table A.9). For identification of carriers/FRDA patients, the Luminex
assay had higher sensitivity (0.963 versus 0.910), specificity (0.957 versus 0.765), PPV
(0.995 versus 0.970), and NPV (0.733 versus 0.500) values compared to the dipstick
assay. NPV values were relatively low both assays again, which is likely attributed to the
relatively low numbers of control samples analyzed. These results suggest that frataxin
measurements from eluted DBS by the Luminex assay to identify carriers and FRDA
patients are more accurate than the dipstick assay, with lower false positive and false
negative rates. We note that both assays perform well, and the method of testing used will
depend on the study context, the clinical setting, and the composition of the study cohort.
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2.5 Discussion
2.5.1 The lateral flow immunoassay shows utility in rapidly measuring frataxin protein
from a variety of cell types
In this chapter, we first used a lateral flow “dipstick” immunoassay to measure
differences in frataxin protein levels between control, known carriers, and FRDA patients
in multiple peripheal cell types. Studies have shown that frataxin protein levels from
peripheral tissues correlate not only with frataxin mRNA, but with frataxin levels in
skeletal muscle in FRDA patients, suggesting that these measurements may be useful as a
valid marker of FRDA disease in affected tissues.139,173 We focused our studies on
measurements from whole blood and cheek swab samples, as they represent two easily
extracted peripheral tissues for the measurement of biomarkers in disease. In each of
these cell types, we found significant differences in frataxin levels between controls,
known carriers, and FRDA patients; we also measured frataxin levels in LOFA patients
and PM patients to elucidate differences, if any, between them and classic FRDA patients
with two GAA repeat expansions and have found significantly higher levels in LOFA
patients compared to the remaining FRDA patients. We measured frataxin levels from
PM patients and found that they did not differ significantly from classic FRDA patient
levels (Table A.10). Frataxin levels in both tissue types correlated with age of onset and
GAA1 repeat length, suggesting that frataxin levels may be an appropriate marker of
disease severity.67
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Based on ROC curve analyses and our own frataxin measurement data, we
generated a set of criteria for classifying measured whole blood and cheek swab samples
as a control, carrier, or FRDA patient. There were different contexts to consider in using
the dipstick assay as a population test. For example, one could only be interested in
identifying FRDA patients in a population, and ignore all of the individuals in the control
or carrier range, or one could identify all carrier and FRDA samples, and ignore all of
those individuals with frataxin levels in the control range. Based on our ROC curve
analyses, the dipstick test is more useful for identifying both FRDA subjects and carriers.
Sensitivities and PPVs were highest in this scenario for both whole blood and cheek
swabs and were comparable between the two cell types. This method of screening avoids
excluding FRDA patients with higher frataxin levels, particularly LOFA patients and
some PM patients, while still maintaining a low false negative rate. In a large-scale
diagnostic setting, a positive result for this test would indicate an individual is either a
carrier or FRDA patient, and could then be subjected to a DNA test to analyze potential
GAA expansions. There may be a few control subjects with lower frataxin levels in the
carrier range; however, in this approach one is less concerned about false positives than
false negatives when screening for FRDA. While we do minimize the rate of false
positives, a positive test on this screening test would only result in a blood draw for DNA
sequencing, a relatively minor procedure. This approach focuses on high positive
predictive value and high sensitivity to reduce the risk of “missing” any FRDA patients in
a screen. We found a low NPV for both cheek swabs and whole blood; however, this
value is heavily influenced by the number of unaffected controls in the study. Cheek
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swab and whole blood samples were collected from much fewer unaffected controls than
carriers and FRDA patients, which in turn underestimate the NPV of the test. In future
clinical studies, the number of unaffected controls sampled will be much larger relative to
the number of false positives found, producing a higher NPV value.
We originally ran standard curves with recombinant frataxin alongside standard
curves of all cell types used for frataxin measurements to not only determine working
concentrations of each cell type, but to quantify absolute frataxin protein levels as well.
Interestingly, commercial recombinant frataxin varied slightly by lot number, so we
expressed data as a percentage of average control frataxin levels instead of absolute
frataxin levels. This method allows us to make comparisons between multiple samples of
the same individual or samples in a group of individuals assuming the same group of
control samples are used to normalize the rest of the samples.
Whole blood and cheek swab samples are easily extractable tissues from
individuals with their own advantages and disadvantages in clinical studies. We showed
that intra-assay, inter-assay, and inter-sample variation is low in whole blood and cheek
swab samples, though we see smaller CV values in whole blood. The relatively higher
variation in cheek swab samples may be attributed to a number of factors; these include
possible presence of extracellular protein in the cheek swab sample, additional error from
protein concentration measurements, and increased CVs from lower absolute frataxin
absorbance values compared to whole blood in spite of similar standard deviation values.
In addition, long-term storage of control samples at -80°C increased variation between
samples to a greater degree in cheek swab samples than in whole blood. There also
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appears to be a “learning curve” associated with collecting cheek swabs samples from
individuals. Samples collected from the Philadelphia area by our own clinical
coordinators typically have a protein concentration between 1.0 and 2.5 µg/µl; samples
collected from off-site locations have a higher percentage of unusable samples – samples
with a total protein concentration of less than 0.4 µg/µl, which results in less than 10 µg
protein in a 25 µl volume required for the dipstick assay. It is possible that shipment of
samples could have resulted in a reduction of sample quality, but this phenomenon is not
seen when our clinical coordinators travel to other sites to collect samples to ship back to
Philadelphia. Furthermore, protein concentrations of cheek swabs do increase as
researchers become accustomed to collecting samples. It is important that researchers at
other institutions educated properly on correct techniques for cheek swab sample
collection to avoid loss of scientifically valuable samples. While frataxin measurements
in whole blood have stronger correlations with age of onset and GAA1 repeat length, less
sample and assay variation, and greater long-term storage stability than cheek swab
samples, the convenient and non-invasive nature of cheek swab collection may present
researchers with a viable alternative in the correct setting; therefore choice of tissue used
for frataxin measurements will depend on the type of study and the materials available.
Taken together, we have shown in this chapter that frataxin measurements from whole
blood or cheek swabs by dipstick assay may be useful population screening and
diagnostic tools and are associated with acceptable levels of variation.
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2.5.2 The Luminex xMAP-based assay may be a useful multicenter screening tool in
whole blood
In addition to our work with the dipstick assay, we also collaborated with Dr.
Devin Oglesbee at the Mayo Clinic to quantify frataxin protein with an xMAP-based
Luminex assay from eluted DBS (Figure 2.2) in controls, carriers, and patients to
determine its utility as a population screening and diagnostic tool compared to the lateral
flow dipstick immunoassay. Frataxin levels from DBS as measured by the Luminex assay
correlated strongly with levels from whole blood measured by the dipstick assay (Figure
2.10C), and were significantly different between controls, carriers, and FRDA patients
(Figure 2.11). ROC curve analyses indicated both assays had areas under the ROC curve
greater than 0.910 (Figure 2.12); however, the Luminex assay demonstrated a higher
sensitivity, specificity, NPV, and PPV compared to the dipstick assay when identifying
carriers and FRDA patients from a cohort (Figure 2.13).
We found inconsistencies in total frataxin levels between the dipstick assay and
Luminex assay when comparing to standard curves based on recombinant frataxin.
Frataxin levels as measured by dipstick assay were approximately two-fold higher
compared to measurements by Luminex assay (~65 pg/µl vs ~30 pg/µl). We were using
commercial recombinant frataxin for our standard curves which may have had impurities
in it, thereby artificially elevating frataxin levels in our samples. The Mayo Clinic
purified and validated their own human frataxin for use in generating a standard curve for
the Luminex assay; therefore, we expressed all values measured by the dipstick assay as a
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percentage of the average controls to place an emphasis on relative amounts of frataxin
between controls, known carriers, and FRDA patients.
There are advantages and disadvantages of using the Luminex assay compared to
the dipstick assay. While both assays performed well in correctly classifying whole blood
or DBS samples, the Luminex assay scored higher for sensitivity, specificity, NPV, and
PPV. The increased accuracy and reduced rate of false negatives and false positives make
this assay attractive for researchers with access to the Luminex technology. In addition,
the nature of the assay allows for multiplexing of tests to investigate multiple markers of
disease. In the future, these could be markers that refine differences between controls,
carriers, and FRDA patients, or markers for other aspects of disease, including insulin
resistance, mitochondrial dysfunction, or myocardial injury. Only a small amount of
blood is required for the Luminex assay, which makes it ideal for a newborn screening
tool to potentially diagnose infants before onset of symptoms. Early diagnosis of FRDA
opens up new cohorts for pharmacological intervention, which may lead to better
prognosis. In contrast, the dipstick assay is clinically useful in multiple cell types,
including the rapidly and non-invasively collected buccal cell extracts from cheek swabs.
Measurements from multiple cheek swab samples are ideal in clinical trial settings where
the patient population may be younger children that are adverse to potentially painful
blood draws; family members of FRDA patients and normal healthy volunteers are also
more likely to donate a cheek swab sample than a whole blood sample. The dipstick
assay is relatively easy and less time-consuming to perform compared to the Luminex
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assay, and the dipsticks can be stored for long periods of time before recording
absorbance measurements.
In this chapter, we have shown that both assays are useful for population
screening and diagnostic purposes and have their own advantages associated with them;
the choice of assay used will therefore depend on the study question of interest, the
composition of the study population, and the study design.
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Figure 2.1 – Schematic for lateral flow immunoassay. (A) Samples are loaded into the
bottom of a 96-well plate, where gold-conjugated frataxin antibodies bind to the frataxin
in the sample. As the sample flows up the dipstick, frataxin is immunocaptured onto the
nitrocellulose portion of the dipstick and can be quantified. (B) Sample dipsticks from
frataxin measurement in buccal cell lysate, and calculations used to express frataxin
levels for our studies. FXN: frataxin, GAM: goat α-mouse.
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Table 2 – Demographic information for whole blood and cheek swab samples collected
from volunteers for frataxin analysis by dipsticks. Detailed information was not obtained
from individuals donating platelets or PBMCs.
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Figure 2.2 – Luminex xMAP-based immunoassay flow chart. Dried blood spot (DBS)
sample eluate was incubated with microspheres coated with a frataxin antibody, and
quantified by measuring fluorescence intensity using a Luminex 200 analyzer.
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Figure 2.3 – Frataxin levels measured using the lateral flow immunoassay from freshly
isolated PBMCs and platelets. (A) Frataxin levels in FRDA PBMCs were significantly
reduced compared to controls (37.6%, p < 0.001). (B) Frataxin levels were reduced in
platelets isolated from carriers and FRDA patients (59.6% and 38.1% of control,
respectively). Patient levels were significantly lower than controls (p < 0.001).

49

Figure 2.4 – Frataxin levels measured using the lateral flow immunoassay from whole
blood. Significant differences were measured between controls and all other groups (p <
0.001), carriers and all other groups (p < 0.05 for LOFA, p < 0.001 for all others), and
FRDA patients and LOFA patients (p < 0.001). LOFA: late-onset Friedreich ataxia, PM:
point mutation FRDA patients.
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Figure 2.5 – Frataxin correlates with age of onset and GAA1 repeat length in whole blood
isolated from FRDA patients. (A) Similarly to cheek swab samples, age of onset
correlated with GAA1 in our study population (R2 = 0.665, p < 0.001). (B) Frataxin
showed stronger associations with age of onset (R2 = 0.407, p < 0.001) and (C) GAA1 (R2
= 0.415, p < 0.001) than in buccal cells.
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Figure 2.6 – ROC curves and classification data from frataxin measurements by dipstick
assay in whole blood. ROC curves for separation of (A) controls from carriers and FRDA
patients and (B) controls and carriers from FRDA patients. (C) 2x2 tables based on
chosen values for classifying samples as “control”, “carrier/potential FRDA”, or
“FRDA”. CTL: control, CR: Carrier.
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Figure 2.7 – Frataxin levels measured using the lateral flow immunoassay from cheek
swab samples. Significant differences were measured between controls and all other
groups (p < 0.001) except non-FRDA MD patients, carriers and all other groups (p <
0.001) except LOFA patients (p < 0.05), and FRDA patients and LOFA patients (p <
0.001). LOFA: late-onset Friedreich ataxia, PM: point mutation FRDA patients, nonFRDA MD: non-FRDA movement disorder patients.
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Figure 2.8 – Frataxin correlates with age of onset and GAA1 repeat length in cheek swab
samples. (A) Confirming previous reports, age of onset correlated with GAA1 in our
study population (R2 = 0.620, p < 0.001). (B) Frataxin showed a moderate association
with age of onset (R2 = 0.229, p < 0.001) and (C) GAA1 (R2 = 0.240, p < 0.001).
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Figure 2.9 – ROC curves and classification data from frataxin measurements by dipstick
assay in buccal cells. ROC curves for separation of (A) controls from carriers and FRDA
patients and (B) controls and carriers from FRDA patients. (C) 2x2 tables based on
chosen values for classifying samples as “control”, “carrier/potential FRDA”, or
“FRDA”. CTL: control, CR: Carrier.
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Figure 2.10 – Correlations from frataxin measurements in FRDA patients by Luminex
assay. (A) In our study population, age of onset correlated strongly with GAA1 (R2 =
0.713, p < 0.001). (B) Frataxin levels as measured by the Luminex xMAP-based assay
correlated strongly with GAA1 (R2 = 0.568, p < 0.001). (C) Frataxin levels from whole
blood as measured by the Luminex xMAP-based assay correlated strongly with frataxin
levels measured using the dipstick assay (R2 = 0.742, p < 0.001).
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Figure 2.11 – Frataxin boxplots comparing frataxin measurement between dipstick and
Luminex xMAP-based assays. Significant differences (p < 0.001 between all groups) in
frataxin levels between controls, carriers and FRDA patients were measured by dipstick
assay (A) and Luminex assay (B).
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Figure 2.12 – Receiver operating characteristic (ROC) curves based on measuring
frataxin from whole blood with the Luminex xMAP-based immoassay (A,C) and dipstick
assay (B,D). ROC curves demonstrate utility as a screening tool based on the area under
the curve when separating (A,B) controls from carriers and FRDA patients and (C,D)
controls and carriers from FRDA patients.
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Figure 2.13 – Classification data based on cutoff values from ROC curves for (A)
Luminex assay and (B) dipstick assay. CTL: control, CR: Carrier.
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Chapter 3: Applications of frataxin measurements in diagnostic and clinical settings
3.1 Abstract
A critical aspect of drug development is the ability to measure changes in
response to therapy. In the last chapter, we demonstrated the ability of the lateral flow
immunoassay to measure differences in frataxin levels between controls, known carriers,
and FRDA patients; however, the sensitivity of the assay to measure changes in frataxin
levels in response to pharmacological interventions or between different genetic
conditions remained untested. In this chapter, we discuss several applications of utilizing
the lateral flow immunoassays in clinical research settings; these include measuring
frataxin levels in atypical patients, measuring changes in response to HDAC inhibitor
treatment, measuring changes in response to combined methotrexate, doxorubicin
(adriamycin), and cisplatin (MAP) chemotherapy in a FRDA patient with comorbid
osteosarcoma, and analyzing effect of HDAC polymorphisms on frataxin levels and
disease phenotype. We found that frataxin protein levels remained relatively stable over
time in controls and FRDA patients, and the lateral flow immunoassay was sensitive
enough to detect changes in frataxin levels in response to drug treatment. We also noted
that frataxin levels showed a slight trend with SIRT6 mutation status, but that these
differences were not significant when accounting for GAA1 repeat length, age and sex,
and likely do not account for all of change in FRDA phenotype seen. Nevertheless, the
lateral flow immunoassay may be a useful complementary diagnostic tool for atypical
patients or for measuring changes in frataxin levels in clinical trial settings. Additionally,
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while single nucleotide polymorphism (SNP) analysis in SIRT genes was inconclusive,
we may be able to analyze other modifiers of frataxin using our immunoassays.
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3.2 Introduction
3.2.1 Friedreich ataxia patients with atypical genetic composition
Approximately 97% of FRDA patients are homozygous for the GAA expansion in
the FXN gene; the majority of the remaining patients are compound heterozygotes with
an expanded GAA repeat on one allele and a point mutation on the other allele.32,47,150
Both are traditionally associated with decreased levels of frataxin, though this has not
been applied to large heterogeneous cohorts. Recently, several heterozygous exonic
deletions have been reported, expanding the known disease-causing spectrum and
indicating that other patients likely carry deleterious mutations that remain to be
characterized.7,63,196,221,223 Here, we describe a subset of atypical FRDA patients without
two known disease-causing mutations. We measured frataxin protein levels via lateral
flow immunoassay in these patients, followed by MLPA analysis on those individuals
with levels in the FRDA patient range to uncover previously undetected deletions. We
also examine frataxin levels in fractionated whole blood from an individual with a 2delT
start codon mutation to investigate the effect of the mutation on frataxin levels in
different cell types. We show that the lateral flow immunoassay has diagnostic utility in
atypical FRDA patients and may be a reasonable complementary tool to use in clinical
settings. As the spectrum for disease-causing mutations continues to expand, we believe
these patients should be under consideration when developing or prescribing potential
therapies for treatment.
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3.2.2 HDAC inhibitors as a potential therapy in Friedreich ataxia
Individuals who are heterozygous carriers of the triplet GAA expansion express
levels of frataxin that are reduced by approximately 50% compared to normal levels, yet
they manifest no clinical symptoms. This suggests that therapeutic approaches that
increase frataxin may be effective even if frataxin is raised only to the level of a carrier.
Small molecule HDAC inhibitor compounds increase histone acetylation at the frataxin
locus and increase frataxin mRNA and protein levels.87 Increases in frataxin mRNA and
protein have been observed in vitro using primary lymphocytes isolated from patient
blood and in FRDA-derived induced pluripotent stem cells (iPS) and neural precursor
cells.159 Beneficial effects of HDAC inhibitors have also been documented in animal
models of FRDA.158,159,178
Performance of later stage clinical trials in FRDA with such agents will require
biological markers of drug response. A variety of clinical measures including
examination based scales and performance measure composites have been validated in
FRDA, but their sensitivity to change as reflected in natural history data is limited.65
Similarly, biomarkers of FRDA are at present limited. Assessment of peripheral frataxin
levels capable of measuring effects of HDAC inhibitors has been utilized, but many of
the practical features of its uses, including short-term and long-term variability
independent of therapy, have not yet been defined.55,139,197,212 In addition, data linking
serial change in neurological outcome measures with frataxin level, confirming frataxin
levels as appropriate targets in the disease, have not yet been obtained.
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In this section, we characterize the stability of frataxin levels over time, the
correlation of frataxin protein levels with disease severity and progression, and the
contribution of frataxin from different components of whole blood. We also report
measurable increases in frataxin mRNA and protein in PBMCs following HDAC
inhibitor treatment, confirming the utility of frataxin protein immunoassays in clinical
trial settings.
3.2.3 MAP chemotherapy and connection to pathophysiology of Friedreich ataxia
While no cure currently exists for FRDA, several potential therapies that aim to
restore frataxin protein or mRNA levels (histone deacetylase inhibitors, gene therapy, and
erythropoietin mimetics) are being investigated.1,87,105,123,198 Interestingly, cisplatin, a
DNA-crosslinking drug used in cancer chemotherapy, can induce expression of both
frataxin mRNA and protein in cisplatin-resistant ovarian carcinoma cell lines to promote
defense mechanisms against reactive oxygen species damage.78 For trials of such agents,
it will be helpful to measure biomarkers to assess disease severity or effectiveness of
potential treatments. Clinically affected tissues are largely inaccessible, so alternatives
are needed. Because frataxin protein measured from peripheral blood parallels levels in
clinically affected tissue, the use of whole blood for frataxin measurements is clinically
relevant as a biomarker.139
As the FRDA population becomes more defined, patients are being identified with
significant concomitant medical illnesses. Some of these diseases and/or their treatments
may interact pathophysiologically with FRDA. Here, we describe an individual with
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FRDA receiving an 8-month course of methotrexate, doxorubicin (adriamycin), and
cisplatin (MAP) chemotherapy. This therapy may intersect the pathophysiology of FRDA
in two ways: first, in the association of increased frataxin levels in vitro with cisplatin
treatment, and second, in the reactive oxygen species-based cardiac disease associated
with doxorubicin, which could potentially synergize with the mitochondrial dysfunction
of FRDA to cause major adverse effects. Anthracycline antibiotics, including
doxorubicin, are known to cause dose-limiting cardiotoxicity, which may exacerbate the
already existent cardiac dysfunction in FRDA patients.187,191 We sought to determine
whether MAP chemotherapy had an effect on FRDA disease state and measured serial
frataxin levels and blood counts to assess changes throughout the course of treatment.
3.2.4 SNP analysis and potential modifiers of frataxin protein
HDAC inhibitors are potentially useful therapeutics for FRDA based on in vivo
and in vitro data from animal models and cells isolated from FRDA patients.87,158,159,178
Polymorphisms in HDAC genes may result in increased frataxin expression or
improvement of FRDA phenotype. Mammalian sirtuins comprise a family of seven
NAD+-dependent deacetylases implicated in the regulation of transcription, DNA repair,
cell survival, cellular stress responses, and metabolism.81 Within this family, SIRT1,
SIRT6, and SIRT7 are localized to the nucleus, SIRT3, SIRT4, and SIRT5 are
mitochondrial, and SIRT2 is cytosolic.81 SIRT6 is involved in regulation of gene
expression, fatty acid metabolism, DNA repair, genome stabilization, and lifespan in
mice.81 SIRT3 knockout mice exhibit global mitochondrial hyperacetylation and
accelerated signs of metabolic syndrome, indicating that SIRT3 is a major mitochondrial
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deacetylase involved in regulating energy and intermediary metabolism.58,88,112 Frataxin
deficiency has been associated with a decrease in mitochondrial acetylated proteins and
altered NAD+/NADH ratios, implying a role for impaired NAD+-dependent deacetylase
activity in FRDA.138,193 Heart homogenates from conditional knockout mouse models of
FRDA also show hyperacetylation that develops progressively with cardiac hypertrophy,
suggesting that impaired SIRT3 deacetylase activity may contribute to lethal
cardiomyopathy in FRDA.209 Marcia Haigis reported at the 4th International Friedreich’s
Ataxia Scientific Conference that overexpression of SIRT3 partially rescued FRDA-like
phenotype in hFXNI154F mutant mammalian cells, decreased mitochondrial ROS
production, and rescued proliferation defects.95 Both sirtuins show deacetylase activity at
specific sites on H3 and H4, which are hypoacetylated near the GAA repeat expansion.
Taken together, these data suggest that sirtuins may represent a potential new target for
pharmacological intervention in treating FRDA through reversible protein acetylation.
We hypothesized that non-synonymous SNPs in HDAC genes may predict FRDA
phenotype and frataxin protein levels. In this section, we analyzed 46 non-synonymous
SNPs in HDAC and SIRT genes from a DNA repository and correlated mutation status
with measures of FRDA disease severity based on the clinical database of the
Collaborative Clinical Research Network in Friedreich’s Ataxia. We measured frataxin
protein via lateral flow immunoassay and investigated the relationship between frataxin
levels and mutation status in selected HDAC genes. We hypothesized that frataxin
protein levels would follow mutation status in those HDAC genes that predict FRDA
disease severity.
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3.3 Materials and Methods
3.3.1 Study approval and informed consent
These studies had approval by the International Review Board at all participating
institutions. All subjects provided written informed consent before participating in study
procedures.
3.3.2 Analysis of atypical FRDA patients
Whole blood and cheek swab samples were collected for frataxin analysis from
individuals with FRDA-like phenotype who did not carry known pathogenic mutations
on each allele. Frataxin protein levels were measured by lateral flow immunoassay as
described in Chapter 2, and those individuals with values in the low FRDA patient range
were screened for possible deletions by MLPA analysis.
MLPA analysis was conducted in the laboratory of Dr. Cathy Stolle. Genomic
DNA was extracted from peripheral blood using an AutoGenFlex STAR automated DNA
extractor (AutoGen, Inc.) or a commercially available kit (Genetra Systems, Inc.)
according to manufacturer's instructions.
Deletion/duplication analysis by MLPA (multiplex ligation-dependent probe
amplification assay) of the FXN gene was performed according to manufacturer's
instructions with a commercially available probe mix (P316-B1, Recessive Ataxias, MRC
Holland, Amsterdam, the Netherlands). In brief, 200 ng of genomic DNA in a final
volume of 5 μl was heated for 5 min at 98°C. After cooling to room temperature, 1.5 μl of
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the probe mix and 1.5 μl SALSA hybridization buffer were added to each sample,
followed by heat denaturation (1 min at 95°C) and hybridization (16 hours at 60°C).
Ligation was performed by adding 32 μl of ligation mix at 54°C for 15 min and the
reaction was stopped by incubating for 5 min at 98°C. PCR amplification was carried out
for 35 cycles in a final volume of 40 μl. PCR products were separated by capillary
electrophoresis using an ABI 3130Xl (Applied Biosystems). An internal size standard
LIZ 600 was used (Applied Biosystems). Two female controls were processed along with
patient samples. Data analysis was performed using GeneMarker v 1.6 (SoftGenetics,
USA). Threshold values were set at 0.75–1.3 for normals, 0.4–0.65 for deletions and 1.4–
1.6 for duplications. For normalization two female control samples were used.
For analysis of a family carrying a start codon deletion (2delT), whole blood was
collected in K2 EDTA BD Vacutainer tubes (REF 367844) and transferred to 15 mL
conical tubes. Blood was spun at 129 g in a swing bucket centrifuge for 15 min with no
brakes. The middle buffy layer was removed and saved to prevent contamination of other
fractions with WBCs. The upper platelet rich plasma (PRP) layer was transferred to a
fresh tube and spun at 341 g in a swing bucket centrifuge for 15 min with no brakes to
pellet platelets. An aliquot of plasma was saved for analysis and stored at -80oC. The
platelet pellet was resuspended in 500 µL PBS and stored at -80oC until use. The
remaining RBC pellet was spun at 341 g in a swing bucket centrifuge for 15 min with no
brakes to remove any residual plasma. RBC pellets were stored at -80oC until use. All
frataxin measurements were performed using the lateral flow immunoassay, the Luminex

68

assay, and western blot analysis in cheek swab, whole blood, and platelet samples as
previously described in Chapter 2.
3.3.3 Short-term frataxin stability and reproducibility analysis
Whole blood from thirty-one FRDA patients at the Children’s Hospital of
Philadelphia was collected in K2 EDTA BD Vacutainer tubes (REF 367844) at baseline,
2 weeks, and 4 weeks for short-term frataxin stability and reproducibility analysis and
stored at -80oC until use. Blood from normal healthy volunteers was collected on a
weekly basis throughout the study. Total protein was extracted by mixing 1 volume of
whole blood to 3 volumes of ice cold extraction buffer A (Abcam/MitoSciences) for 15
min at 4oC. Samples were microcentrifuged 5 min at 13,000 g and cleared supernatant
was saved for analysis. Samples were further diluted 1:10 in extraction buffer A
(Abcam/MitoSciences) for frataxin measurement by lateral flow immunoassay as
described in Chapter 2. We used paired t-tests to measure differences in frataxin levels
between patient visits. Analysis of long-term frataxin stability and effect of HDAC
inhibitor treatment on PBMCs was conducted by Repligen Corporation.
3.3.4 Clinical monitoring in a FRDA patient with osteogenic sarcoma
A woman with FRDA at the University of California at Los Angeles Medical
Center was diagnosed with osteosarcoma by bone biopsy after an X-ray and MRI
following knee pain revealed a possible tumor. This patient underwent six months of
combined chemotherapy at the Kaiser Permanente Medical Center. All patient
information used in this study was provided by her neurologist, oncologist, and family.
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Frataxin protein levels were measured throughout the study from whole blood and cheek
swab samples as described in Chapter 2. Blood cell counts and cardiac parameters were
also assessed throughout the duration of the study at the Kaiser Permanente Medical
Center, and changes in parameters were assessed using linear regression.
3.3.5 Effect of HDAC gene polymorphisms on FRDA phenotype
We used the Collaborative Clinical Research Network in Friedreich’s Ataxia
clinical database to analyze the association between HDAC gene polymorphisms and
features of FRDA including age of onset, FARS score, performance measures Z2
(composite of reciprocal-scored 9-hole peg test and reciprocal-scored timed 25-foot walk
z-scores) and Z3 (composite of Z2 and low-contrast letter acuity vision test z-score), and
presence of diabetes, cardiomyopathy or scoliosis. Genomic DNA from 458 subjects
across multiple sites was genotyped at 46 non-synonymous SNPs in HDAC genes
(HDAC10, HDAC5, SIRT3, SIRT5, SIRT6), and SNP scores were assigned based on
mutation status. Frataxin protein levels were measured from whole blood and cheek swab
samples as described in Chapter 2 for as many patients as possible. Simple and multiple
regression analyses were used to analyze relationships between SNP scores and measures
of disease phenotype accounting for GAA repeat length, age at sample collection, and
age of onset.
3.3.6 Statistical analysis
Data analysis was performed using STATA SE 11 software and MS Office Excel
2007. Frataxin levels were expressed as percentage of average control.
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3.4 Results
3.4.1 Immunoassays exhibit diagnostic utility in patients with atypical Friedreich ataxia
Approximately 96-98% of all FRDA patients carry an expanded GAA repeat on
both alleles of the FXN gene, while the remaining 2-4% are compound heterozygotes for
an expanded GAA repeat on one allele and a deleterious point mutation within the FXN
gene on the other allele.32 During the course of our work, we identified ten patients with
FRDA-like phenotype who did not have typical pathogenic mutations identified on each
allele, including two individuals with only a single point mutation. Seven of these
patients had reduced frataxin protein levels as detected in buccal cell samples by lateral
flow immunoassay, with six in the low FRDA patient range (Table 3.1). For the purpose
of our study, we classified these individuals as “atypical” FRDA patients.
We screened six of these atypical patients for a possible deletion in the FXN gene
using MLPA analysis (Table 3.1). Four of the six patients tested were negative for any
deletions within the FXN gene; however, two patients carried novel deletions
encompassing FXN exons (Figure 3.1). In one patient (P.A.001), we identified a
heterozygous deletion that included exons 2 and 3 as indicated by a decrease in
amplification of the associated primer pairs (Figure 3.1A). A second patient (P.A.005)
was found to carry a heterozygous exon 5 deletion (Figure 3.1B). These mutations both
appear to be deleterious as indicated by low frataxin levels and FRDA-like phenotype the
patients display. No changes were seen in peak amplitudes of genes not involved in
FRDA (SETX and APTX). These data further confirm the wide spectrum of deleterious
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FXN mutations and indicate that other patients likely carry deleterious mutations that
remain to be characterized.
As shown in Chapter 2, frataxin protein levels measured in cheek swab samples
correlate well with levels measured from whole blood; however, it might be possible that
certain mutations may lead to an altered frataxin protein that is upregulated in cells with a
high turnover rate. Curiously, we consistently found a large difference between whole
blood (62.8% of control) and buccal cell (4.5% of control) frataxin protein levels in one
severely affected atypical patient (P.A.002) that has no expanded alleles and a 2delT start
codon mutation on one allele (Table 3.1). To determine the source of extra frataxin in
blood, we fractionated fresh whole blood from P.A.002 as well as his parents and two
siblings and measured frataxin from buccal cells, whole blood, platelets, and the RBC
pellet (Figure 3.2A). We found that the RBC pellet, which is assumed to contain very low
levels of mitochondria, was responsible for the elevated frataxin level seen in whole
blood in P.A.002 (Figure 3.2B). Interestingly, the father (who also carries the 2delT
mutation) and one sibling of P.A.002 also have elevated whole blood (139.9% and
128.6% of average control, respectively) and RBC pellet frataxin levels (127.1% and
112.7% of average control, respectively), suggesting that the start codon mutation in FXN
leads to increased immunoreactive frataxin in red blood cells through an unknown
mechanism.
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3.4.2 Frataxin protein levels remain stable over time and are increased in response to
HADC inhibitor therapy
In Chapter 2, we found that frataxin levels measured in whole blood from a
control sample were stable over the course of three years (Table A.7). In order to evaluate
what effect potential therapies would have on frataxin levels over baseline changes, we
sought to determine whether frataxin levels in FRDA patients were also unchanging, or if
they varied with normal progression of disease. First, we examined short-term stability of
frataxin in whole blood from FRDA patients, by measuring frataxin levels via dipstick
assay from a cohort of 31 FRDA patients at 0, 2, and 4 week visits, and using paired ttests to compare frataxin levels between visits (Figure 3.3). The cohort covered a wide
spectrum of disease severity, with age of onset ranging from 5-41, and GAA1 repeat
length ranging from 126-901 repeats. As in Chapter 2, we found correlations between age
of onset and GAA1 repeat length (R2 = 0.794, p < 0.001, Figure 3.3A), GAA1 repeat
length and frataxin (R2 = 0.583, p < 0.001), and age of onset and frataxin (R2 = 0.385, p <
0.001). Based on paired t-test comparisons, frataxin levels did not differ between 0 and 2week visits (p = 0.892), 2 and 4-week visits (p = 0.191), or 0 and 4-week visits (p =
0.257) for this cohort (Figure 3.3B). Similarly, Dr. Jim Rusche’s group at Repligen
Corporation has reported that weekly frataxin protein and mRNA measurements from
five FRDA patients and five related carriers do not vary significantly over a 15-week
period (data unpublished). To assess long-term stability of frataxin in FRDA patients, we
followed frataxin levels from a representative patient over the course of three years and
found that levels did not significantly change between measurements during this time
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(Table A.11). Taken together, we show that frataxin levels measured in whole blood from
FRDA patients remain stable over a length of time predicted to be relevant for clinical
trial studies.
Since frataxin levels appear to be stable over time and correlate well with GAA1
repeat length and age of onset, we investigated whether frataxin levels would predict
severity of disease as measured by FARS scores. In a linear regression model accounting
for patient age and sex, we found a significant relationship between frataxin levels in
whole blood with baseline FARS scores (n=94, p < 0.001, R2 = 0.245). This finding was
supported by the correlation between GAA1 and baseline FARS scores (p < 0.001, R2 =
0.441), which suggests patients with longer GAA repeats and lower frataxin levels
present with a more severe neurological phenotype.
We then investigated whether frataxin levels would predict the rate of disease
progression, as measured by rate of change in FARS scores. FARS scores were shown to
increase at an average rate of 6.2 ± 7.4 points per two-year period.69 Age, but not GAA1
repeat length, was a significant predictor of change in FARS scores, indicating younger
patients change faster; the relationship between GAA1 repeat length and rate of
progression may have been confounded by more severely affected patients approaching
the ceiling for FARS scores.69 How these rates change over longer periods of time or
depend on frataxin levels remain unclear. Here, we have expanded upon these findings
and hypothesized that less severely affected patients with lower frataxin levels would
have slower disease progression as evidenced by a smaller change in FARS score per
year. To capture an accurate, potentially linear rate of progression, we excluded patients
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with less than two years of FARS measurements (with fewer than three total visits) to
reduce variation in disease progression and patients with FARS scores greater than 100 to
eliminate a possible ceiling effect. We found an overall rate of change in FARS scores of
2.3 ± 2.5 points per year in patients with frataxin measurements (n=94), similar to the
previously reported rate (Table 3.2).69 Age was a significant determinant in disease
progression; of FRDA patients with recorded frataxin measurements, adults progressed
significantly slower (1.9 ± 2.0 points per year) than children under the age of 18 (3.7 ±
3.3 points per year, p = 0.003). On their own, frataxin levels did not predict change in
FARS scores (p = 0.503); however, when using multivariate regression analysis to assess
the effect of frataxin levels on rate of FARS change with respect to age and sex, we found
the model to be statistically significant (p = 0.002) with age as the main predictor of
progression (p < 0.001) and frataxin levels approaching significance (p = 0.095).
Knowing that frataxin levels remain stable over time is advantageous for certain
clinical trials where measured frataxin protein is used as an outcome measure. If frataxin
protein levels change in response to pharmacological intervention, then those changes can
be attributed to the drug. If the lateral flow immunoassay is sensitive enough to detect
these changes, then these measurements will be a useful biomarker for response of
treatment in FRDA patients. Repligen Corporation has been testing RG2833, a class one
HDAC inhibitor designed to upregulate the frataxin gene, as a potential therapy for
FRDA, and utilized the dipstick assay to measure changes in frataxin expression in
response to RG2833 treatment.195 RG2833 induced a dose-dependent increase in frataxin
mRNA (n=47) and protein levels (n=27) in PBMCs isolated from FRDA patients, with
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10 µM treatment causing a two-fold increase in expression on average (Figure 3.4A,B).
PBMC response to treatment did not correlate with GAA1 repeat length, indicating that
RG2833-induced increases in frataxin protein and mRNA are independent of disease
severity (Figure 3.4C,D). While these are simply preclinical results that will accompany
phase I testing in subjects, it still shows that the dipstick assay can detect small changes
in frataxin protein levels from FRDA cells in response to pharmacological intervention,
and suggests that this assay may be useful in clinical trials where frataxin protein is an
outcome measure of interest.
3.4.3 MAP chemotherapy does not significantly worsen cardiac parameters in FRDA
We also used the dipstick assay to monitor frataxin levels in a FRDA patient
receving potentially frataxin-altering treatment for other conditions to determine if our
assay could detect changes in frataxin protein levels.
A 19-year-old woman developed balance and gait difficulties at age 9 and was
subsequently diagnosed with Friedreich ataxia at age 13. She carried GAA repeat lengths
of 700/1000, and baseline frataxin protein levels in whole blood and buccal cells were
20.5% of control. Hypertrophic cardiomyopathy, scoliosis of 35 degrees, and pes cavus
were present at baseline evaluation in 2008. This patient began using a walker at age 16.
Her initial Friedreich Ataxia Rating Scale (FARS) score was 65.5, corresponding to an
individual with overt and significant symptomatology, including the need for assistance
with ambulation. At that time, she was on a supplement-based regimen, including vitamin
E, alpha lipoic acid, and coenzyme Q10.
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At the age of 19, this individual presented with right leg pain after a fall.
Evaluation with X-ray and MRI revealed a lesion of the distal femoral metaphysis on the
medial side, which was confirmed to be osteosarcoma by bone biopsy. She was treated
with 8 months of MAP chemotherapy (Table 3.3), which included methotrexate (12 g/m2;
weeks 4, 5, 9, 10, 15, 16, 20, 21, 24, 25, 28, 29), doxorubicin (37.5 mg/m2; weeks 1, 6,
12, 17, 22, 26) and cisplatin (60 mg/m2; weeks 1, 6, 12, 17). After initial therapy, her
primary lesion was removed at week 11. Throughout therapy, she experienced alopecia,
oral mucosal irritation, neutropenic fevers, and constipation. After therapy, no residual
tumor was noted. She had no worsening cardiac symptoms, and although her gait was
altered by removal of a portion of her femur, subjectively she had no increase in her
neurologic symptomatology.
As cisplatin therapy may increase frataxin levels in vitro, we followed frataxin
protein levels over time using both whole blood and cheek swab samples collected during
the course of treatment to assess any drug-induced increases or decreases in frataxin
protein levels. Because frataxin levels remained relatively stable in control and Friedreich
ataxia patient samples over the course of several weeks (Tables A.7 and A.11), any
changes in frataxin from baseline levels could be attributed to the MAP therapy. Average
frataxin levels measured from whole blood and buccal cells were significantly lower than
control (28.57% and 12.48%, respectively, p < 0.001). Frataxin levels in buccal cells at
the end of the study remained relatively unchanged (Figure 3.5) when compared with
before chemotherapy (13.3% and 16.8%, respectively), though slight variations were seen
throughout the study; these may be attributed to drug-induced oral mucosal irritation. In
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whole blood, frataxin levels increased from approximately 10% of control to over 40% of
control after Day 50 of treatment and remained elevated through Day 170 (Figure 3.5).
No whole blood samples were available for frataxin protein analysis after Day 170.
As frataxin levels in blood are associated with several different cell types
(platelets, white blood cells, and red blood cells), changes in frataxin levels might simply
reflect a change in the relative proportion of these cells in blood as caused by her
treatment. Hematocrit, hemoglobin, and red blood cell count decreased during treatment,
with an increased red blood cell distribution width above normal limits (Figure 3.6).
Although white blood cell count decreased slightly, levels remained within the normal
range. Mean corpuscular volume remained unchanged, while platelet count decreased
slightly toward the end of 8 months of treatment (R2 = 0.459, p = 0.004), consistent with
a general thrombocytopenia associated with chemotherapy (Figure 3.7).
The anthracycline class of antibiotic drugs, including doxorubicin, is associated
with cardiotoxicity due to reactive oxygen species production, which seems highly likely
to exacerbate the cardiac deficits already associated with Friedreich ataxia. Cardiac
parameters, including intraventricular septum thickness, ejection fraction, and left
ventricular posterior wall thickness, were evaluated before, during, and after treatment
via echocardiogram to ensure cardiac function did not worsen with MAP therapy (Table
3.4). Intraventricular septum thickness was not significantly altered before or during
MAP therapy (p = 0.773). Ejection fraction did not deviate from the normal range during
treatment, and importantly, did not significantly decrease (p = 0.418). Left ventricular
posterior wall thickness increased slowly before, during the course of therapy, and after
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completion (p = 0.012); intraventricular and left ventricular posterior wall thickness were
both above normal before start of treatment. Thus, during this short follow-up period,
doxorubicin did not markedly worsen cardiomyopathy in this patient.
3.4.4 SNP analysis of SIRT6 and SIRT3 in FRDA reveals potential modifiers of the FXN
gene
We investigated whether non-synonymous polymorphisms in HDAC genes were
associated with FRDA disease phenotype and frataxin protein levels. Genomic DNA
from 458 subjects across multiple sites was genotyped at 46 non-synonymous SNPs in
HDAC genes (HDAC10, HDAC5, SIRT3, SIRT5, SIRT6), and SNP scores were assigned
based on mutation status. The Collaborative Clinical Research Network in Friedreich’s
Ataxia clinical database was used to analyze the association between HDAC gene
polymorphisms and features of FRDA including age of onset, FARS score, performance
measures Z2 and Z3, reciprocals of the 9-hole peg test and timed 25-foot walk, and lowcontrast letter acuity vision (Table 3.5). Of the 46 SNPs analyzed, 42 were identical in the
study population, suggesting a homogenous ethnic background. The SIRT6
polymorphism rs352493, which results in a Ser46Asn amino acid change found in
approximately 10-15% of the population, predicted FARS, Z2 and Z3 scores when
controlling for age, sex, and GAA1 repeat length (p < 0.005). This polymorphism was
completely linked to a second polymorphism in CREB3L3 (rs352117) that also predicted
FRDA phenotype. Patients heterozygous for the asparagine residue (carrying the Ser46
form) have a less severe neurological phenotype than patients homozygous for
asparagine. No individuals were found to be homozygous for the Ser46 form. The SIRT3
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polymorphism (rs1045288), which has a minor allele frequency of approximately 20%,
was slightly associated with age of onset (p < 0.08) and the Z3 composite score (p =
0.156). The HDAC10 polymorphism (rs34402301) has a minor allele frequency of
approximately 3% and was minimally associated with FARS scores (p = 0.084), lowcontrast letter acuity vision (p = 0.068), and age of onset (p = 0.1534). While the SIRT3
and HDAC10 SNPs had slight predictive value for some neurological performance
measures, only the relationship between the SIRT6 polymorphism rs352493 and disease
phenotype reached statistical significance.
We next investigated whether frataxin protein levels correlated with SIRT6
(rs352493), SIRT3 (rs1045288) or HDAC10 (rs34402301) mutation status to determine a
possible role for HDAC polymorphisms in modifying frataxin expression as a means to
alter disease progression. We initially measured frataxin in whole blood from a small
subset of patients with different SIRT6 mutation status (Figure 3.8A), and found that
patients heterozygous for the serine residue had higher levels of frataxin protein
compared to those homozygous for asparagines (mean 36.4%, 29.4% of control,
respectively). While not statistically significant (p = 0.365), this trend supports our earlier
findings of Ser46 predicting less severe phenotype, and the results appeared encouraging;
however, this was a preliminary study with a small number of patients, and we did not
have clinical information on these individuals to determine whether frataxin levels were
influenced by GAA repeat length. We expanded our study to measure frataxin levels in
buccal cells and whole blood from over one hundred patients with known SIRT6 mutation
status to investigate whether a similar trend held for a more meaningful sample size
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(Figure 3.8B,C). Similar to our preliminary studies, frataxin levels measured from buccal
cells and whole blood were higher in the S/N group (25.2% and 36.3% of control,
respectively) compared to the N/N group (20.9% and 29.5% of control, respectively), but
these differences were not statistically significant (p = 0.249 and 0.167, respectively).
When including GAA1 repeat length, age and sex to correct for clinical differences
between the two groups, the regression model becomes statistically significant in both
buccal cells and whole blood (p < 0.001); however, this significance was driven mainly
by GAA1 repeat length (p < 0.001), and not SIRT6 mutation status (p = 0.060 and 0.604,
respectively). Patients in the S/N group did have a higher mean age of onset than the N/N
group (17.0 vs 13.4), and the difference was statistically significant (p = 0.026), which
may account for some of the trend in frataxin levels. Predictably, patients in the S/N
group also had a shorter mean GAA repeat length on the shorter allele than the N/N
group (620.8 vs 556.7), but these differences were also not significant (p = 0.122).
We also measured frataxin levels by mutation status in HDAC10 (rs34402301)
and SIRT3 (rs1045288) SNPs; however, no significant differences in frataxin levels were
predicted based on mutation status in buccal cells or whole blood for either gene (Figure
3.9A-D). When accounting for GAA1 repeat length, age, and sex, the regression models
assessing predictive value of SIRT3 mutation status on frataxin levels were significant for
in buccal cells and whole blood, but significance was again driven mainly by GAA1
repeat length and not SIRT3 mutation status (p = 0.554 and 0.705, respectively).
Similarly, while the regression model was significant, the rs34402301 SNP in HDAC10
does not appear to predict frataxin levels in buccal cells or whole blood when including
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GAA1 repeat length, age, and sex in the analysis (p = 0.211 and 0.836, respectively).
Taken together, while polymorphisms in HDAC genes appear to predict neurological
severity as measured by the FARS exam or other performance measures, these
differences may not be influenced by changes in measured frataxin protein levels.

82

3.5 Discussion
3.5.1 Diagnostic utility of immunoassays in patients with atypical Friedreich ataxia
Our first application of the lateral flow immunoassay was measuring frataxin
levels in suspected FRDA patients with an atypical genetic composition. We collected
cheek swab and/or whole blood samples from patients with FRDA-like phenotype and
zero or one known disease-causing mutation to determine if frataxin protein levels were
in the low FRDA patient range. In seven out of ten atypical patients, frataxin protein
levels were reduced, with frataxin levels below 20% of average controls in six of these
individuals (Table 3.1). DNA from six atypical patients with reduced frataxin levels were
submitted for MLPA analysis to determine whether there were any deletions present in
exons of the FXN gene. We found a novel heterozygous partial exon 2/3 deletion in
atypical patient P.A.001, and a heterozygous exon 5 deletion in atypical patient P.A.005
(Figure 3.1). Because these individuals had low measured frataxin protein levels, we
anticipate that these deletions result in an absence of frataxin synthesis or a rapid
degradation of a mutated form of frataxin, although it may be possible for the deletions to
eliminate or cover the frataxin epitope. We must also consider the possibility that the
other four patients testing negative in the MLPA analysis may actually be carriers that
registered positive for low frataxin in the immunoassay. The carrier frequency for FRDA
is approximately 1:100, so they could have potentially been in the low range of carrier
frataxin levels; however, these individuals have a phenotype resembling FRDA,
suggesting that they more likely have an as yet undetected mutation resulting in disease
either in the promoter region or in another gene that modifies frataxin expression.
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P.A.010 had a measured frataxin level of “0%” of control, which means their frataxin
levels were below the assay’s limit of detection. As complete knockout of frataxin is
expected to be lethal based on animal models, we can assume P.A.010’s frataxin level to
be nonzero.
We also discovered a large discrepancy between frataxin levels in buccal cells and
whole blood from an atypical patient (P.A.002) with a start codon mutation (2delT)
inherited from his father on one allele with no other known disease-causing mutations. To
investigate the source of increased whole blood frataxin in this individual, we
fractionated whole blood to measure frataxin levels in platelets and the RBC pellet in
P.A.002 and his family. Surprisingly, the RBC pellet contained elevated frataxin levels
(Figure 3.2) in P.A.002, his father, and one sibling relative to other cell types, suggesting
that the start codon mutation results in an increased level of extramitochondrial frataxin
through an as yet unidentified mechanism. Zhu, et al presented a case of a compound
heterozygote with a GAA expansion of ~900 repeats on one allele, with the same 2delT
start codon mutation on the other allele.221 In both cases, the siblings and parents carrying
the start codon deletion were unaffected. The authors hypothesized that this deletion may
create an alternate start codon that results in a truncated form of frataxin missing its Nterminal mitochondrial targeting sequence; however, it was not determined whether this
form of frataxin was expressed. This hypothesis is consistent with our finding that
frataxin in the RBC pellet, which contain very few mitochondria, was elevated only in
individuals carrying the deletion. We still do not know what the second disease-causing
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mutation is in P.A.002, which may be severe enough to cause a compensatory
upregulation of frataxin in cells that rapidly turn over.
The lateral flow immunoassay shows utility as a complementary diagnostic tool,
and can be used before more invasive or more expensive diagnostic tests are
administered. However, certain mutations may result in elevations of frataxin in whole
blood through unknown biochemical mechanisms. These results amplify the importance
of testing in individuals with any kind of idiopathic ataxia, and for testing in multiple cell
types to avoid miss diagnosing potential FRDA patients. Taken together, these reports
indicate that the spectrum of mutations for FRDA is wider than originally anticipated.
More research must be done to uncover the effect these mutations have on frataxin
protein structure and function to determine which therapeutic strategy may be most
beneficial.
3.5.2 Longitudinal frataxin measurements and response to HDAC inhibitor therapy
We next determined whether our use of the dipstick assay was sensitive enough to
detect changes in frataxin protein levels in response to pharmacological intervention, so
that the assay may show utility in clinical trials where frataxin protein is an outcome
measure. We first examined frataxin levels over time to determine if there was a basal
change in FRDA patients; however, we found that frataxin levels remained stable in
control, carrier, and patient blood samples over a period of up to four years as evidenced
by low CV values and no significant differences in measurements between patient visits.
These data suggest that frataxin levels may be set from an early age, and any changes in
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response to treatment are likely a result of that agent. To determine whether the dipstick
assay shows utility in measuring changes in response to treatment, Repligen Corporation
treated PMBCs isolated from FRDA patients with RG2833, a class I HDAC inhibitor
designed to upregulate frataxin expression.195 While RG2833 successfully induced a
dose-dependent increase in frataxin mRNA and protein in PBMCs, it is unclear if these
changes in frataxin levels are clinically meaningful, and the increase in frataxin
expression is probably associated with increased expression of multiple genes.44
However, these results show the dipstick assay can detect small changes in frataxin
protein in peripheral tissues in response to drug treatment, and may show utility in
clinical trials where change in frataxin protein in an outcome measure of interest.
FARS scores are often used in clinical studies to assess baseline severity of
neurological disease and its response to treatment; however, correlation of frataxin levels
with FARS scores and its rate of change had not yet been thoroughly explored. That
frataxin levels appeared to be unchanging over time was an interesting result, and we
investigated whether frataxin levels could predict the severity of disease as measured by
baseline FARS scores, and rate of disease progression, as measured by the rate of change
in FARS score per year. If so, frataxin levels could represent a biomarker for not only
disease severity, but for progression as well. We found that GAA1 (p < 0.001, R2 = 0.441)
and frataxin levels (p < 0.001, R2 = 0.245) both correlated with baseline FARS scores in a
linear regression model accounting for patient age and sex, which suggest patients with
longer GAA repeats and lower frataxin levels have a more severe neurological phenotype
controlling for age.
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For examination of disease progression, certain criteria were required for patients
to be included in analysis to increase the chance that we were actually examining a linear
rate of change. In our analysis, we included only individuals with more than two years of
FARS data to reduce overall variation, and excluded those patients with FARS scores less
than 20 or greater than 100 to reduce confounding floor and ceiling effects of the rating
scale. We also eliminated patients with potential biochemical confounding
characteristics, including two patients with G130V and I154F point mutations and one
LOFA patient with chronic lymphocytic leukemia, which increases WBC count and
artificially elevates frataxin levels in whole blood relative to cheek swab samples. We
found an overall rate of FARS change of 2.3 ± 2.5 points per year, similar to the average
progression of 2.6 points per year seen between year one and two in a previous study
(Table 3.2).69 This suggests rates of change may be linear after the first two years until
scores approach the ceiling of the scale. We hypothesized that more severely affected
patients, those with longer GAA repeats and lower frataxin levels, would show a more
rapid progression manifested as a larger change in FARS score per year compared to less
severely affected individuals; we would also expect scores to plateau as they approach
the ceiling of the scale after several years. Our finding that adult patients progressed
slower than children under 18 (1.9 ± 2.0 and 3.7 ± 3.3 points per year, respectively)
seemed to reinforce this theory, as older patients are typically those who develop the
disease later in life and are less severely affected than children, or are patients who
developed FRDA early on and have since reached the ceiling of the scale and thus, no
longer demonstrate rapid progression. We did not find a significant difference in rate of
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FARS change between males and females (2.2 ± 2.1 and 2.3 ± 2.7, respectively; p =
0.904). Previous studies following the first two years of progression noted sex differences
possibly attributed to muscle strength; since we only analyzed patients with two or more
years of FARS scores, muscle strength may no longer be able to compensate for
progression of ataxia. Finally, we used multivariate regression analysis to assess the
effect of frataxin levels on rate of FARS change accounting for age and sex. The model
was statistically significant (p = 0.002), with age as the main predictor of disease
progression (p < 0.001) and frataxin levels approaching significance (p = 0.095);
however, age is complicated by the fact that we don’t see LOFA patients at a young age.
All young patients are affected individuals; older patients are not only LOFA patients
presenting with their first symptoms, but patients in their second or third decade of
disease. As natural history studies progress and more complete clinical data are recorded
on current and newly diagnosed patients, accuracy of relationships between disease
parameters will only improve. Early diagnosis of FRDA and consistent monitoring of
disease progression through measurement of FARS scores and frataxin levels is vital for
accurately assessing disease progression, both naturally and in response to
pharmacological intervention. While many clinical trials point to a decrease in absolute
FARS scores as a sign of improvement in response to treatment, it may now be possible
to conduct long-term studies to determine whether agents that increase frataxin levels
also affect predicted rate of progression.
In this section, we have not only shown that measured frataxin levels appear to be
relatively stable over time, but that the lateral flow immunoassay can be used to detect
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changes in frataxin levels in response to pharmacological intervention. Frataxin levels
from whole blood also correlate strongly with baseline FARS scores and rate of change in
FARS scores when accounting for patient age. Taken together, frataxin measurements
from whole blood may be a useful biomarker for assessing disease severity and
progression in FRDA patients. This is useful not only for natural history studies, but in
clinical trials where treatments aimed to increase frataxin levels are investigated for their
properties to reduce progression of disease.
3.5.3 MAP Chemotherapy and FRDA
In this chapter, we also followed an individual with FRDA undergoing
chemotherapy for osteosarcoma and measured frataxin protein levels from whole blood
and cheek swab samples during the course of 8 months of treatment. Since the 1980s,
most treatment regimens for osteosarcoma have consisted of a combination of
methotrexate, doxorubicin, and cisplatin, referred to as MAP chemotherapy.92 Cisplatin is
a cancer chemotherapeutic agent that induces apoptosis through formation of platinumDNA adducts that inhibit DNA replication and transcription.219 Cisplatin may also induce
frataxin expression in ovarian carcinoma cell-lines through promotion of defense
mechanisms against reactive oxygen species-induced damage.78 While these agents are
vital for treatment of osteosarcoma, it remained unclear as to what effects the
chemotherapy would have on FRDA disease state and frataxin protein levels, in
particular. In this patient, frataxin protein levels in buccal cells are similar pre- and posttreatment, with any fluctuations likely associated with therapy-induced oral mucositis.
Frataxin protein levels in whole blood appeared to increase after Day 50 of treatment.
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This is potentially consistent with the studies in cell lines, but the exact cause of elevated
frataxin levels is unclear. These changes could be a result of drug-induced frataxin
increase, but also could represent possible selection for blood cells containing higher
levels of frataxin, either by selecting cells with shorter GAA repeats or by changing the
maturational state of circulating blood cells. Still, the data clearly show that MAP
chemotherapy does not suppress frataxin synthesis further than at baseline.
Doxorubicin (adriamycin), another component of MAP chemotherapy, is a
member of the anthracycline class of antibiotics that exerts its cytotoxic effects through
intercalation of DNA, interfering with replication and slowing proliferation of tumor
cells.9,133 Cardiac toxicity after treatment for osteosarcoma is exclusively caused by
doxorubicin, potentially through increased free radical production and oxidative stress.92
Since cardiac hypertrophy and an increased sensitivity to oxidative stress are already
hallmarks of FRDA, doxorubicin treatment could potentially exacerbate disease
progression. One of the agents in trials for therapy of cardiomyopathy in FRDA,
deferiprone, is protective against doxorubicin-induced cardiotoxicity in animals,
suggesting a link between the mechanisms of FRDA and doxorubicin cardiomyopathy.
However, there was no systematic loss of cardiac function or significant hypertrophy in
this subject, allaying fears that FRDA and doxorubicin may synergistically cause
progressive cardiac disease. While already outside the normal range, intraventricular
septum thickness did not significantly change during treatment. Left ventricular posterior
wall thickness increased during treatment; however, the change during treatment was
similar in magnitude to that of before and after treatment, suggesting normal progression
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of hypertrophy in FRDA. Mean ejection fraction increased during treatment, but returned
toward baseline after treatment; importantly, the ejection fraction remained within normal
range throughout the duration of the study.
This patient’s family reported that her neurological symptoms improved during
the treatment course, but formal neurological assessment is confounded by effects of
disease and by the surgical intervention on her femur. Still, we are able to report that an
individual with FRDA can undergo MAP chemotherapy without the risks of significantly
worsened cardiac parameters, neurological deterioration, or further lowering of frataxin
levels.
3.5.4 SNP analysis of SIRT6 and SIRT3 in FRDA
Finally, in this chapter we examined the potential predictive value of sirtuin gene
polymorphisms on FRDA disease severity and frataxin protein levels. Regression models
showed that a Ser46Asn polymorphism in SIRT6, in which FRDA patients carry the
Ser46 residue, predicted a less severe neurological phenotype when controlling for age,
sex, and GAA1 repeat length; patients heterozygous for the asparagine residue had a less
severe neurological phenotype than patients homozygous for asparagines as determined
by multiple neurological parameters, including Z2 and Z3 performance measures, FARS
scores, and reciprocal-scored 9-hole peg test and timed 25-foot walk. There were minor
associations approaching significance between SIRT3 polymorphism (rs1045288) and age
of onset and the Z3 composite score. Similarly, the HDAC10 polymorphism
(rs34402301) was also minimally associated with FARS scores, low-contrast letter acuity
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vision, and age of onset, though these relationships were also not statistically significant.
SIRT3 and HDAC10 SNPs only had slight predictive value for these performance
measures, and mostly had an impact on nonneurological features (data not shown). Only
the relationship between the SIRT6 polymorphism rs352493 and disease phenotype
reached statistical significance.
Next, we investigated whether mutation status in the above HDAC genes
predicted frataxin protein levels. When accounting for GAA1 repeat length, age, and sex,
we found that our regression model to assess the predictive value of SIRT6 mutation
status on frataxin levels was statistically significant (p < 0.001), suggesting that patients
with asparagine residues express higher levels of frataxin protein. However, this
relationship is largely driven by GAA1 repeat length and not mutation status based on pvalues from our regression model. Polymorphisms in SIRT3 and HDAC10 did not
significantly predict disease phenotype, but there were minimal associations between
mutation status and a subset of parameters that approached significance, including age of
onset, Z3 composite scores, FARS scores, and low-contrast letter acuity vision. Our
regression models to determine whether SIRT3 or HDAC10 polymorphisms predicted
frataxin levels when accounting for GAA1 repeat length, age, and sex were again
significant (p < 0.001); however, these relationships were driven largely by GAA1 repeat
length, and not by frataxin levels (p = 0.705 and 0.836 for SIRT3 and HDAC10 in whole
blood, respectively). However, even though we now have genotyped 505 patients, we
have only measured frataxin protein from whole blood in 181 of them. As the minor
allele frequency of the SNPs of interest occur is between 10-20%, this means we have a
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small number of measured frataxin levels from patients that carry these mutations in
SIRT6 (n=20), SIRT3 (heterozygous n=69, homozygous n=14), and HDAC10 (n=22).
This could result in wider confidence intervals and may not accurately reflect true
differences between mutation statuses. We will need to collect blood samples for frataxin
measurements from as many of the remainder of these patients as we can to obtain a
larger sample size with less variation.
In summary, while the Ser46Asn polymorphism in SIRT6 leads to a less severe
neurological phenotype, it may not be heavily influenced by a change in frataxin protein
levels. Future research will need to examine the effect this polymorphism has on SIRT6
expression levels and/or function to elucidate the connection between mutation and
phenotype. In the meantime, the dipstick assay may be useful for detecting differences in
frataxin levels within a patient population based on difference in mutations or expression
of other modifiers of the FXN gene, including transcription factors and other cis-acting
binding elements.45,107,143,156
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Table 3.1 – Clinical information and frataxin levels of suspected FRDA patients with
atypical genetic presentation. Patients with low frataxin levels were further analyzed by
MLPA.
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Figure 3.1 – Multiplex Ligation-Dependent Probe Amplification analysis of FRDA
patients with suspected atypical genetic composition (Table 3.1) has expanded the
spectrum of known mutations in the FXN gene, including (A) a heterozygous partial
exon2/3 deletion in one patient and (B) a heterozygous exon 5 deletion in another FRDA
patient. SETX and APTX are genes involved in ataxia-ocular apraxia, and were used as a
control for FRDA.
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Figure 3.2 – Frataxin analysis of the family of an atypical FRDA patient with a start
codon mutation (2delT) on one allele, and an unknown mutation on the other. (A) The
lateral flow immunoassay was used to measure frataxin from buccal cells, whole blood,
RBC pellets, and platelets of the atypical patient, his family, and representative controls
(n=3). (B) Whole blood and RBC pellet frataxin levels are elevated in the atypical
patient, his father, and one sibling relative to platelet and cheek swab frataxin levels.
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Figure 3.3 – Short-term stability of whole blood frataxin levels in FRDA patients (n=31).
Frataxin levels were measured at baseline (0 weeks), 2 weeks, and 4 weeks. (A) Age of
onset correlated strongly with GAA1 repeat length in our patient cohort (R2 = 0.794, p <
0.001). Frataxin levels also correlated with age of onset (R2 = 0.385, p < 0.001) and
GAA1 repeat length (R2 = 0.583, p < 0.001). (B) FRDA patient frataxin levels remained
stable over four weeks, showing no statistical differences between 0 and 2 weeks (p =
0.892), 2 and 4 weeks (p = 0.191), and 0 and 4 weeks (0.257).
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Table 3.2 – Baseline FARS scores and rate of neurological progression measured in
FRDA patients. Patients were included only if they had more than two years of FARS
data, and excluded if FARS scores were less than 20 or greater than 100 to reduce
confounding floor and ceiling effects of the rating scale. Patients with potential
biochemical confounding characteristics were also excluded. FARS: Friedreich ataxia
rating scale.
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Figure 3.4 – Dose-dependent effect of HDAC inhibitor RG2833 on frataxin mRNA and
protein levels in PBMCs isolated from FRDA patients. (A) FRDA PBMCs (n=47) show a
dose-dependent increase in average frataxin mRNA and (B) frataxin protein expression
(n=27). Error bars represent standard deviation. (C,D) Fold change of mRNA and protein
did not correlate with GAA1 repeat length, suggesting frataxin increases were
independent of disease severity. This figure was adapted from experiments performed by
Repligen Inc.
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Table 3.3 – MAP chemotherapy treatment schedule; Week 1 marks period that first
treatment was received. Drugs were administered in sodium chloride 0.9% IV
(doxorubicin) or IVPB (cisplatin). High-dose methotrexate was followed by leucovorin
rescue to minimize methotrexate toxicity
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Figure 3.5 – Frataxin levels in cheek swabs and whole blood isolated from a FRDA
patient with osteosarcoma during and after treatment with MAP chemotherapy. Day 1
marks first treatment.
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Figure 3.6 – Blood composition of a FRDA with osteosarcoma before and during MAP
chemotherapy. Day 1 marks first treatment. WBC: white blood cells, RBC: red blood
cells.
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Figure 3.7 - Blood composition of a FRDA with osteosarcoma before and during MAP
chemotherapy. Day 1 marks first treatment.
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Table 3.4 – Cardiac parameters before, during, and after MAP chemotherapy. Day 1
marks day that first treatment was received. IVS: intraventricular septum thickness, EF:
Ejection Fraction, LVPW: left ventricular posterior wall thickness; Measurements made
at the Kaiser Permanente Medical Center.
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Table 3.5 – Associations of HDAC gene polymorphisms with parameters of FRDA
disease progression. Cells are color-coded to represent p-values of less than 0.2 (yellow),
0.1 (light orange), 0.05 (dark orange), and 0.01 (red). AOO: age of onset, 9HPT: 9-hole
peg test, T25W: timed 25-foot walk, FARS: Friedreich ataxia rating scale, LCLA: lowcontrast letter acuity.
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Figure 3.8 – Frataxin boxplots by SIRT6 (rs352493) mutation status in whole blood and
cheek swab samples. (A) Initial experiments showed increased frataxin in the S/N group
compared to the N/N group (mean 36.4%, 29.4% of control, respectively; P = 0.365).
Frataxin levels measured from (B) buccal cells and (C) whole blood were higher in the
S/N group (25.2% and 36.3% of control, respectively) compared to the N/N group
(20.9% and 29.5% of control, respectively), but these differences were not statistically
significant (p = 0.249 and 0.167, respectively). Frataxin levels in buccal cells and whole
blood were not predicted by SIRT6 mutation status when accounting for GAA1 repeat
length, age, and sex (p = 0.060 and 0.604, respectively).
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Figure 3.9 - Frataxin boxplots by HDAC10 (rs34402301) and SIRT3 (rs1045288)
mutation status in whole blood and cheek swab samples. No significant differences in
frataxin levels were detected between mutation status in whole blood or buccal cells for
either (A, B) SIRT3 or (C, D) HDAC10.
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Chapter 4: Investigation of mitochondrial metabolism in Friedreich ataxia
4.1 Abstract
The lack of useful biomarkers of FRDA pathogenesis has hindered the analysis
and development of effective treatments. A growing body of evidence suggests that
metabolic dysfunction may contribute to or result from FRDA pathogenesis, yet there is
no rapid assay to quantify these changes. In this chapter, we used SILEC methodology to
characterize changes in CoA species in frataxin siRNA knockdown HEK293 cells as well
as freshly isolated human platelets. We found significant increases in succinylCoA:acetyl-CoA ratios in both HEK293 frataxin knockdown cells and platelets isolated
from FRDA patients relative to controls. We then performed isotopic labeling with [U13

C6]-glucose and [U-13C16]-palmitic acid in HEK293 knockdown cells and human

platelets and fibroblasts to determine relative flux of mitochondrial short-chain acyl-CoA
metabolites. A decrease in [U-13C6]-glucose-derived acetyl-CoA and an increase in [U13

C6]-glucose-derived succinyl-CoA was measured in frataxin knockdown HEK293 cells

compared to scrambled siRNA controls. [U-13C16]-palmitic acid-derived acetyl-CoA was
increased in frataxin knockdown HEK293 cells and FRDA fibroblasts compared to
controls, but was decreased relative to controls in FRDA platelets. These experiments
represent the first time changes in acyl-CoA species were measured in FRDA platelets
and fibroblasts, and suggest that there is a rearrangement of metabolic pathways in
unaffected cell types in FRDA. This methodology can be expanded to include a broader
set of metabolites to further characterize changes in metabolism in FRDA and other
mitochondrial disorders. By understanding metabolic rearrangement in FRDA, we can
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develop new biomarkers of disease and potentially uncover novel targets for drug
development or understand mechanisms of FRDA pathogenesis.
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4.2 Introduction
4.2.1 LC/MS and stable isotope labeling overview
Liquid chromatography (LC) coupled with tandem mass spectrometry (MS)
provides a highly sensitive means for separation and measurement in proteomic analyses,
and is a useful tool for measuring thousands of analytes from a single biological
sample.89 Matrix effects on analyte stability, extraction, and ionization efficiency are
evident in any MS-based measurement of endogenous metabolites, and require the use of
appropriate internal standards that mimic the physiological and biochemical analytes of
interest.94,126,155,162 The use of a stable isotope-labeled analog of a compound is an ideal
internal standard, as it is identical to the compound of interest except for mass; structural
analogs are undesirable as internal standards, as they exhibit different retention times and
ionization properties compared to the analyte of interest.39 However, these stable isotopic
analogs had been difficult to synthesize. Stable isotopic labeling of amino acids in cell
culture (SILAC) is a method that was developed to generate a library of heavy-labeled
proteins for use as internal standards.142 In this method, cells are grown in culture media
in which unlabeled amino acids are replaced with their heavy-labeled form. The labeled
form of the amino acids are exclusively incorporated into cellular proteins through
protein synthesis, and result in an almost purely labeled set of proteins after multiple
passages.142 The cells can be lysed to produce a stable isotope labeled proteome internal
standard (SILAP), which can be extracted from the cell culture and spiked into
experimental samples at a known concentration to quantify proteins of interest.77,146 The
samples are analyzed by MS, and the relative levels of labeled and unlabeled proteins of
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interest can be distinguished and measured. Recently, the SILAC methodology was
adapted by Dr. Sanka Basu in Dr. Ian Blair’s lab to synthetically generate a series of
labeled coenzyme A (CoA) species for detection and quantification of CoA and shortchain acyl-CoA thioesters through LC/MS analysis.13,14 This technique, stable isotope
labeling by essential nutrients in cell culture (SILEC), was developed by growing cells in
culture media with coenzyme A precursor pantothenate replaced by [13C315N1]pantothenate to construct a series of heavy-labeled CoA thioesters that can be extracted
and utilized as LC/MS internal standards for endogenous short-chain acyl-CoA species.
4.2.2 Applications of SILEC and isotopic labeling in mitochondrial metabolism
CoA thioesters are intracellular biomolecules involved in several metabolic
pathways of the mitochondrion, including the citric acid cycle (acetyl-CoA and succinylCoA), ketogenesis pathway (acetoacetyl-CoA, HMG-CoA), branched chain amino acid
metabolism, and fatty acid biosynthesis and degradation (short, medium, and long chain
acyl-CoA species) (Figure 4.1). Changes in these CoA species may be indicative of
pathological or physiological metabolic dysfunction, and can potentially be used as a
marker of mitochondrial disease. For example, the mitochondrial complex I inhibitor
rotenone, used in models of Parkinson’s disease, induced a dose-dependent decrease in
succinyl-CoA and an increase in β-hydroxybutyryl-CoA in multiple human cell lines.12
Rotenone also inhibited biosynthesis of [U-13C6]-glucose-derived [13C ]-acetyl-CoA and
[13C ]-succinyl-CoA in isotopic tracer analysis of SH-SY5Y neuroblastoma cells,
suggesting compensatory metabolic rearrangement in a model of mitochondrial
dysfunction.12
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Metabolic dysfunction and decreased energy capacity likely play a role in several
mitochondrial disorders, including FRDA. A proteomic study from hearts of frataxin
knockout mice recently revealed a rearrangement of mitochondrial energy metabolism,
including decreased expression of components of complex I/II and increased expression
of enzymes involved in compensatory pathways of branched chain amino acid
metabolism, pyruvate decarboxylation, ketone body catabolism, and the citric acid
cycle.201 In addition, gene expression profiles from PBMCs in FRDA patients and
carriers revealed altered expression of genes involved in lipid metabolism, which may
represent a compensatory mechanism for energy production when ATP production
through the ETC is insufficient.44 Interestingly, these changes were detected in the
absence of a degenerative phenotype, suggesting rearrangements in metabolism are a
result of reduced frataxin levels, and not massive cell loss. These findings, coupled with
the observation that tissues most affected in FRDA have high energy demands, indicate
that FRDA patients are subject to dysfunctional mitochondrial metabolism.
Like frataxin protein, CoA thioesters are intracellular species, and require
extraction from affected cells or tissues for biomarker analysis. While frataxin protein is
ubiquitously expressed, FRDA is a disease that primarily involves cardiomyocytes and
neurons of the dorsal columns, both of which are located in clinically inaccessible tissues.
As a result, surrogates that reflect disease state are needed to substitute for pathologically
affected tissue types. While these surrogate tissues may not exhibit the pathological
disease phenotype, they must express the analyte of interest and be of easy access for
repeated sampling. Accessible tissues and cells typically used in FRDA biomarker studies
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include whole blood, PBMCs, primary lymphocytes and fibroblasts, and buccal cells.
Total cellular protein extracted from whole blood and buccal cells was used as described
above for frataxin analysis, but these cell types may not contain enough mitochondria for
quantitative CoA thioester analysis. Primary fibroblast cultures and platelets isolated
from whole blood are both extractable mitochondria-containing cell types that can be
used for baseline LC/MS analysis of CoA species, as well as isotopic tracer LC/MS
analysis to assess changes in metabolic flux.
Since aconitase and complex II are ISC-containing enzymes of the citric acid
cycle that are affected in FRDA, we hypothesized that dysfunctional mitochondrial
metabolism may occur as exhibited by changes in short-chain acyl-CoA thioester levels
between control and FRDA samples. In this section, we used SILEC internal standards
with LC/MS analysis to measure the baseline differences in the CoA profile between
control and frataxin knockdown HEK293 cells, as well as between platelets isolated from
control and FRDA subjects. We also utilized isotopic tracer analysis coupled with
LC/MS to characterize relative differences in metabolic flux in transfected HEK293 cells,
platelets, and primary fibroblast cultures.
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4.3 Materials and Methods
4.3.1 HEK293 cell culture, siRNA knockdown, and isotopic labeling
HEK293 cells were maintained in low-glucose MEM (GIBCO) supplemented
with 7.5%/2.5% FBS/HS (Foundation/GIBCO), 1% pen strep (GIBCO), and 200 nM Lglutamine (GIBCO) at 37°C, 5% CO 2 . Within 24 hours, when cells had reached 40-50%
confluency, cells were transfected for 48 hours with frataxin (Ambion, 144470) or
negative control Silence pre-designed siRNAs (Ambion, Negative Control siRNA #1)
using Lipofectamine 2000 reagent (Invitrogen) in Opti-MEM (GIBCO). Knockdown
success was verified by western blot using an antibody directed toward mature frataxin
protein (Abcam/MitoSciences) as described in Chapter 2, and was expressed as a
percentage of frataxin in parallel control samples. Prior to solid phase extraction (SPE)
purification and LC/MS analysis, cells were collected in PBS and spiked with 0.2 mL
acid extracted SILEC internal standards.
For isotopic labeling in HEK293 cells, culture medium was removed and replaced
with labeling medium immediately before siRNA transfection. Unlabeled control cells
were cultured in low-glucose (1 mg/mL) DMEM (GIBCO) supplemented with 15% FBS
(Foundation), 1% pen strep (GIBCO), and 200 nM L-glutamine (GIBCO) at 37°C, 5%
CO 2 . To label glucose, HEK293 cells were grown in the glucose-free DMEM (GIBCO)
supplemented with 1 mg/mL [U-13C 6 ]-glucose (Sigma-Aldrich), 15% FBS (Foundation),
1% pen strep (GIBCO), and 200 nM L-glutamine (GIBCO) at 37°C, 5% CO 2 . For
analysis of labeled palmitic acid-derived acyl-CoA species, HEK293 cells were cultured
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in low-glucose (1 mg/mL) DMEM (GIBCO) supplemented with 100 µM [U-13C 16 ]palmitic acid (Sigma-Aldrich), 15% FBS (Foundation), 1% pen strep (GIBCO), and 200
nM L-glutamine (GIBCO) at 37°C, 5% CO 2 . After incubation for 72 hours at 37°C, cells
were collected in 1 mL PBS (GIBCO) and spun down for 5 min at 13,000 g. Cell pellets
were resuspended and sonicated in 1 mL of 10% TCA for short-chain acyl-CoA
extraction or 3:1 acetonitrile (ACN):isopropanol for long-chain acyl-CoA extraction then
spun down for 5 min at 13,000 g. The supernatant was transferred to a new
microcentrifuge tube and stored at -80°C until use for acyl-CoA SPE purification and
LC/MS analysis.
4.3.2 Platelet isolation and preparation
FRDA patients were recruited by the Friedreich Ataxia Research Alliance
(FARA) and were seen at the Children’s Hospital of Philadelphia as part of an ongoing,
multicenter natural history study. In addition, age-matched volunteers were used as
controls. All subjects provided written informed consent before participating in study
procedures. Blood was collected in 8.5 mL glass ACD Solution A Vacutainer tubes (BD
Biosciences, REF 364606) and transferred into 15 mL centrifuge tubes. Blood was spun
at 129 g in a swing bucket centrifuge for 15 min with no brakes. The upper platelet rich
plasma (PRP) layer was transferred to a fresh tube and spun at 341 g in a swing bucket
centrifuge for 15 min with no brakes to pellet platelets. Platelets were resuspended and
sonicated in 1 mL of 10% trichloroacetic acid (TCA) to extract short-chain acyl-CoA
species, then spun down for 5 min at 13,000 g. The supernatant was transferred to a new
microcentrifuge tube and stored at -80°C until use for short-chain acyl-CoA analysis.
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Prior to solid phase extraction (SPE) purification and LC/MS analysis, samples were
thawed and spiked with 0.2 mL acid extracted SILEC internal standards (Figure 4.2).
For isotopic labeling of freshly isolated human platelets, blood was collected in
8.5 mL glass ACD Solution A Vacutainer tubes (BD Biosciences, REF 364606) and
transferred into 15 mL centrifuge tubes. Stocks of isotopic tracers were added to whole
blood for final concentrations of 1 mg/mL [U-13C6]-glucose (Sigma-Aldrich) or 100 µM
[U-13C16]-palmitic acid (Sigma-Aldrich). Samples were inverted to ensure mixing of
tracer in blood, incubated for 1 hour at 37°C, and platelets were isolated and processed
for LC/MS analysis as described above (Figure 4.2).
4.3.3 Human fibroblast cell culture and isotopic labeling
Control (GM08402) and FRDA (GM03816, GM03665) fibroblast cell lines from
Coriell Institute for Medical Research were generously donated to us by Dr. Grazia
Cotticelli and Dr. Rob Wilson. Clinical and demographic information for these
individuals was obtained from the Coriell Institute (Table A.12). The GM03816 line
represents a milder FRDA phenotype, with a GAA 1 repeat length of 330, and the
GM03665 line is derived from a more severely affected patient with an earlier onset of
disease and a GAA 1 repeat length of 780. Fibroblasts were maintained in low-glucose
DMEM (GIBCO) supplemented with 15% FBS (Foundation), 1% pen strep (GIBCO),
and 200 nM L-glutamine (GIBCO) at 37°C, 5% CO 2 . Twenty-four hours after human
fibroblasts were passaged, culture medium was removed and replaced with labeling
medium and processed as described above for HEK293 cells.
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4.3.4 Short- and Long-chain acyl-CoA purification
Extraction of CoA species and LC/MS analysis were performed in the laboratory
of Dr. Ian Blair. To purify short-chain acyl-CoA species using a vacuum manifold, Oasis
HLB SPE columns were pre-conditioned with 1 mL methanol and equilibrated with 1 mL
H2O. The TCA-extracted lysates (supernatants) were loaded to the columns, and washed
1x with 1 mL H2O. CoA compounds were eluted with 2x 0.5 mL 25 nM ammonium
acetate in methanol into fresh glass tubes. Samples were dried under N2 and resuspended
in 50 µL 5% 5-SSA.
To purify long-chain acyl-CoA species using a vacuum manifold, Sigma Supelco
2-(2-pyridyl)ethyl silica gel SPE columns were preconditioned with 1 mL
ACN/isopropanol/H2O/acetic acid (9:3:4:4 v:v:v:v). ACN-extracted lysates were treated
with 0.25 mL KH2PO4 and spun at 16,000 g. Supernatants were transferred to glass tubes,
and 0.125 mL glacial acetic acid was added, and acidified extracts were added to each
column. Columns were washed with 2.5 mL ACN/isopropanol/H2O/acetic acid (9:3:4:4
v:v:v:v), and samples were eluted with 1 mL 4:1 methanol:250 mM ammonium formate
into fresh glass tubes. Samples were dried under N2, resuspended in 50 µL 50:50 ACN:
H2O, then vortexed and sonicated for 5 minutes in a bath sonicator before LC/MS
analysis.
4.3.5 LC/MS analysis
Short-chain acyl-CoA species were separated using a reversed phase Phenomenex
HPLC Luna C18 column 2.0 x 150 mm, pore size 5 μm (Waters HPLC XBridge C18
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column 2.0 x 150 mm, pore size 3 μm for long-chain acyl-CoA species) with 5 mM
ammonium acetate in water as solvent A, 5 mM ammonium acetate in 95/5
acetonitrile/water (v/v) as solvent B (100% acetonitrile for long-chain acyl-CoA species)
and 80/20/0.1 (v/v/v) acetonitrile/water/formic acid as Solvent C. Gradient conditions
were as follows: 2% B for 1.5 min, increased to 25% over 3.5 min (50% for long-chain
acyl-CoA species), increased to 100% B in 0.5 min and held for 8.5 min, washed with
100% C for 5 min, before equilibration for 5 min. The flow rate was 200 μL/min.
Samples were analyzed using an API 4000 triple quadrupole mass spectrometer (Applied
Biosystems, Foster City, CA) in the positive ESI mode. Samples (10 μL) were injected
using a Leap CTC autosampler (CTC Analytics, Switzerland) where they were
maintained at 4°C, and data was analyzed with Analyst 1.4.1 software. The column
effluent was diverted to the mass spectrometer from 8 min to 22 min and to waste for the
remainder of the run. The mass spectrometer operating conditions were as follows: ion
spray voltage (5.0 kV), compressed air as curtain gas (15 psi) and nitrogen as nebulizing
gas (8 psi), heater (15 psi), and collision-induced dissociation (CID) gas (5 psi). The ESI
probe temperature was 450°C, the declustering potential was 105 V, the entrance
potential was 10 V, the collision energy was 45 eV, and the collision exit potential was
15 V. Transitions (m/z) for precursor → product ions for the LC-SRM/MS analyses were
as follows: CoASH (768.1 → 261.1), [13C315N1]-CoASH (772.1 → 265.1), acetyl-CoA
(810.1 → 303.1), [13C315N1]-acetyl-CoA (814.1 → 307.1), propionyl-CoA (824.1 →
317.1), [13C315N1]-propionyl-CoA (828.1 → 321.1), malonyl-CoA and BHB-CoA (854.1
→ 347.1), [13C315N1]-malonyl-CoA and [13C315N1]-BHB-CoA (858.1 → 351.1), succinyl118

CoA (868.1 → 361.1), [13C315N1]-succinyl-CoA (872 → 365.1), HMG-CoA (912.1 →
405.1), and [13C315N1]-HMG-CoA (916.1 → 409.1). Isotopomer distribution analysis of
short chain acyl-CoA species was performed as described previously.12
4.3.6 Statistical Analysis
LC/MS data was analyzed with Analyst 1.4.1 software. Concentrations were
determined from regression lines of standard curves and normalized for protein
concentration. Statistical analysis was performed using STATA SE 11 software and MS
Office Excel 2007. Student’s t-test was used to compare mean values between control
and FRDA cells.
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4.4 Results
4.4.1 siRNA knockdown of frataxin in HEK293 cells results in altered acyl-CoA profile
HEK293 cells were transfected with either frataxin siRNA or a negative control
scrambled siRNA, and knockdown efficiency was assessed by Western blot analysis.
After 48 hours, frataxin levels were significantly reduced to approximately ~20% of
control (Figure 4.3).
Transfected HEK293 cells were processed for measurement of static levels of
short-chain acyl-CoAs as described in the Methods section. As the cells were cultured in
6-well-plates instead of 10 cm dishes, only the most abundant CoA species (CoASH,
Acetyl-CoA, and succinyl-CoA) could be detected and analyzed by LC/MS. We
measured a significant decrease (p < 0.05) in the acetyl-CoA:succinyl-CoA ratio in
frataxin knockdown cells compared to scrambled negative controls (Figure 4.3).
4.4.2 Acyl-CoA measurements from freshly isolated human platelets
Since platelets are rich in mitochondria containing CoA thioesters and have
reduced frataxin levels in FRDA, we hypothesized that freshly isolated platelets could be
used to screen for baseline differences in CoA profiles. In order to preserve metabolic
function of platelets, isolation was simplified to a two-step centrifugation process before
labeling with SILEC standards (Figure 4.2). Platelets from FRDA patients had
significantly decreased frataxin protein levels (p < 0.001) and increased succinyl-CoA
levels compared to controls. There was no absolute difference in acetyl-CoA levels
(Figure 4.4). When normalized to acetyl-CoA levels to control for variations in blood
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volume and platelet count between individuals, the ratio of acetyl-CoA:succinyl-CoA
was significantly reduced in FRDA platelets compared to controls (p < 0.05), consistent
with changes seen in frataxin siRNA-treated HEK293 cells. No differences were noted
for other short-chain acyl-CoA species. Acetyl-CoA:succinyl-CoA ratios did not correlate
with frataxin levels or GAA1 repeat length, but showed a significant correlation with
FRDA patient age (p = 0.024, R2 = 0.416). A regression model to analyze the relationship
between acetyl-CoA:succinyl-CoA ratios and frataxin in FRDA patients accounting for
sex and age approached statistical significance (p = 0.075, R2 = 0.559), but the
relationship was driven largely by age (p = 0.062) and not by frataxin levels (p = 0.893).
Interestingly, the correlation between age and acetyl-CoA:succinyl-CoA was not
significant in controls (p = 0.594), suggesting that changes in mitochondrial metabolism
may be enhanced over time in a reduced frataxin environment; however, the sample size
will need to be increased to further characterize these relationships.
4.4.3 Isotopic tracer analysis can assess mitochondrial metabolic flux in control and
FRDA cells
The changes in CoA profiles described above only provide a “snapshot” of
mitochondrial metabolism at any given time, and do not indicate how changes in
metabolic pathways are occurring. To obtain information about changes in flux of
metabolism in mitochondria, we used isotopic tracer analysis to measure levels of acylCoA species derived from [U-13C6]-glucose or [U-13C16]-palmitic acid. Transfected
HEK293 cells were used first to test whether we could detect labeling of short-chain acylCoA species in FRDA cell models. HEK293 cells were transfected with either frataxin
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siRNA or a negative control scrambled siRNA, and knockdown efficiency was assessed
by Western blot analysis similar to the above experiment. After 72 hours, frataxin levels
were significantly reduced to 16.0 ± 2.5% of control in unlabeled cells, 37.8 ± 7.0% of
control in [U-13C6]-glucose labeled cells, and 58.1 ± 5.0% of control in [U-13C16]-palmitic
acid labeled cells (Figure 4.5A). To assess metabolic flux, HEK293 cells were labeled
with 1 mM [U-13C6]-glucose immediately before transfection, and grown in the labeling
media for 72 hours. We measured a significant decrease in labeled acetyl-CoA (p = 0.03)
and a significant increase in labeled succinyl-CoA (p = 0.04) in frataxin knockdown cells
relative to negative controls (Figure 4.5B). The increased succinyl-CoA in frataxin
knockdown cells is consistent with our results from baseline acyl-CoA measurements
above, and suggests that either glucose-derived acetyl-CoA is being utilized to produce
succinyl-CoA, or there is an increase in alternate pathways to generate succinyl-CoA
such as beta-oxidation of fatty acids or branched chain amino acid catabolism. To
investigate whether metabolism of fatty acids is altered in a cellular model of FRDA, we
measured levels of short-chain CoA species derived from [U-13C16]-palmitic acid in
transfected HEK293 cells. HEK293 cells were labeled with 100 µM [U-13C16]-palmitic
acid immediately before transfection, and grown in the labeling media for 72 hours. We
found a significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA in frataxin
knockdown cells compared to scrambled siRNA controls (22.0% vs 11.7%, p = 0.02;
Figure 4.5C). We did not detect significant labeling of other short-chain acyl-CoA
species by [U-13C16]-palmitic acid. Taken together, these results suggest that frataxin

122

knockdown in HEK293 cells results in a potential compensatory shift in mitochondrial
metabolism towards increased fatty acid oxidation.
We next examined the steady-state differences in acyl-CoA levels between
controls and FRDA patient samples. We initially used platelets as they represent easily
extracted, mitochondria-rich cells that demonstrate altered metabolism in response to the
complex I inhibitor rotenone [Basu 2012, unpublished]. To validate labeling of CoA
species in platelets, we treated whole blood drawn from controls with [U-13C6]-glucose
and [U-13C16]-palmitic acid for 1 hr at 37°C, and measured the percentage labeling of
short-chain acyl-CoA species (Figure 4.6A). Neither low (1 mg/mL) nor high (4.5
mg/mL, data not shown) concentrations of [U-13C6]-glucose resulted in significant
labeling over untreated controls, while 100µM [U-13C16]-palmitic acid resulted in
approximately 10-25% of short-chain CoA species, suggesting platelets may rely more
heavily on fatty acid oxidation than glycolytic catabolism of glucose to generate actylCoA. We next compared metabolism between control and FRDA platelets (n=6) by
measuring isotopic labeling of short-chain acyl-CoAs derived from a 100µM [U-13C16]palmitic acid. Frataxin protein was significantly reduced in FRDA platelets relative to
control (36.5 ± 2.9% of control) as measured by dipstick assay (Figure 4.6B). There were
significant decreases in labeling of succinyl-CoA in M2 (p = 0.01) and 3-HMG-CoA in
M2 (p = 0.03) and M4 (p = 0.004), with a nonsignificant decrease in acetyl-CoA labeling
in M2 in FRDA platelets relative to control (Figure 4.6C). No labeling of CoASH in
either control or FRDA platelets was seen, signifying the labeling was not a result of
[13C] incorporation into the CoA moiety. There was no relationship between patient
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frataxin levels, age of onset, or GAA1 repeat length and level of acyl-CoA labeling,
which may be attributed to the small sample size and/or homogeneity of clinical features
amongst the six patients (Table A.13). Taken together, these results suggest an inability
for platelets to take up or metabolize glucose, with a potential deficiency in fatty acid
metabolism in FRDA platelets. While platelets appear to demonstrate utility for
assessment of fatty acid metabolism, we were unable to detect any [U-13C6]-glucosederived short-chain acyl-CoA species, which may indicate that different cell types rely on
different metabolic pathways.
We moved into patient and control fibroblasts obtained from the Coriell Institute
for short-chain acyl-CoA isotopomer analysis derived from [U-13C6]-glucose. We initially
performed a time-course experiment with 1 mg/mL [U-13C6]-glucose in fibroblast culture
media to determine an optimal time before labeling of acetyl-CoA reached a plateau
(Figure 4.7A). We found that approximately 21.4% of acetyl-CoA was labeled (M2) in
control fibroblasts at 48 hours and 24.6% after 72 hours, demonstrating a decreased rate
of isotopic enrichment between 48 and 72 hours (Figure 4.7A). Similarly, approximately
17.7% of acetyl-CoA was labeled (M2) in FRDA fibroblasts at 48 hours and 19.8% after
72 hours, also showing a decreased rate of isotopic enrichment between 48 and 72 hours
(Figure 4.7A). These data suggest that labeling fibroblasts in the presence of an isotopic
tracer for 48-72 hours would be sufficient for steady state labeling of target short-chain
acyl-CoA species without noticeable toxicity. We then measured the percentage of [U13

C6]-glucose-derived acetyl-CoA (M2) in one control and two FRDA fibroblast cell lines

at 72 hours to assess whether there were any significant changes in metabolism of
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glucose to acetyl-CoA in a FRDA model (Figure 4.7C). Both control and FRDA
fibroblasts showed approximately ~15% of acetyl-CoA labeled as M2, with no significant
differences in labeling between the control line (GM08402) and a moderately affected
FRDA patient (GM03816, p = 0.894) or a more severely affected patient (GM03665, p =
0.639) (Figure 4.7C). We were unable to detect significant labeling of any other shortchain acyl-CoA species derived from [U-13C6]-glucose in fibroblasts. Next, we cultured
control and FRDA fibroblasts in the presence of [U-13C16]-palmitic acid for isotopomer
analysis to determine if there were significant differences in fatty acid metabolism
between controls and patients. Similar to [U-13C6]-glucose, we performed a time-course
experiment with 100 µM [U-13C16]-palmitic acid in fibroblast culture media to
approximate an optimal time for incorporation of the 13C label into acetyl-CoA, and
found that sufficient labeling was seen after 72 hours (Figure 4.7B). There was a
significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA in the FRDA
GM03665 fibroblast line compared to control GM08402 fibroblasts (45.9% vs 27.6%, p
= 0.004), suggesting fatty acid oxidation is increased in FRDA fibroblasts in response to
low levels of frataxin protein (Figure 4.7D).
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4.5 Discussion
In this chapter, we used SILEC internal standards and LC/MS to measure the
short-chain acyl-CoA profile in transfected HEK293 cells, platelets isolated from FRDA
patients and control subjects, and primary FRDA and control fibroblast cell lines. As
mitochondrial dysfunction is believed to play a role in FRDA pathogenesis, we
hypothesized that there would be significant changes in metabolism, as detected by shortchain acyl-CoA levels normalized to SILEC internal standards, between patients and
controls to potentially compensate for any deficiencies in mitochondrial energy
metabolism.
Our focus was on succinyl-CoA and acetyl-CoA, two abundant acyl-CoA species
that are easily analyzed by LC/MS, and are key metabolites in major pathways in
mitochondria. Glycolysis/pyruvate decarboxylation and fatty acid oxidation are two
major sources of acetyl-CoA, which then enters the citric acid cycle and is consumed for
energy production. Succinyl-CoA is an intermediate in the citric acid cycle formed by
decarboxylation of α-ketoglutarate by α-ketoglutarate dehydrogenase, and is converted to
succinate by succinate thiokinase. Succinyl-CoA can also be formed from carboxylation
and rearrangement of proprionyl-CoA, an end product of odd-chain fatty acid oxidation.
Activities of the ISC-containing enzymes aconitase and succinate dehydrogenase are
reduced in some tissues in FRDA, which may in turn alter levels of intermediates in the
citric acid cycle.22,167 Since succinyl-CoA is downstream of aconitase in the citrate acid
cycle, we hypothesized that energy production through the citric acid cycle would be
impaired and baseline succinyl-CoA levels would be decreased in FRDA samples relative
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to controls, similar to rotenone-mediated changes in multiple human cell lines.12
Surprisingly, we found the opposite: a significant decrease in acetyl-CoA:succinyl-CoA
ratios in FRDA platelets relative to controls resulting mainly from an increase in
succinyl-CoA, which was supported by similar in vitro findings in transfected HEK293
cells. While the exact mechanism behind these changes in acyl-CoA profiles is unclear, it
may involve rearrangement of compensatory pathways to overcome deficiencies in the
citric acid cycle.201 This compensation may involve increases in citric acid cycle enzyme
gene expression, odd-chained fatty acid oxidation or α-ketoglutarate production through
anaplerotic pathways to bypass deficiencies in aconitase.118,127 On the other hand, a
buildup of succinyl-CoA could be the result of decreased conversion to succinate,
suggesting further impairment of the citric acid cycle downstream of succinyl-CoA,
which may be partially attributed to decreased enzyme activity of succinate
dehydrogenase.22 Although platelets are clinically unaffected in FRDA, we still see
reduced frataxin levels and changes in CoA profiles. Though we did not see significant
correlations between acetyl-CoA:succinyl-CoA ratios and frataxin levels or GAA1 repeat
length, we did find a strong correlation between acetyl-CoA:succinyl-CoA ratios and age
of FRDA patients. A regression model investigating frataxin, age, and sex as predictors
for acetyl-CoA:succinyl-CoA ratios approached statistical significance, with age
appearing to be the main contributor to the relationship. In controls, the correlation
between age and acetyl-CoA:succinyl-CoA was not significant; this result is potentially
interesting, suggesting that age itself is a stressor that can bring out changes in acyl-CoA
levels in cells with reduced frataxin protein. However, we must also consider our small
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sample size when drawing conclusions from these early studies. Taken together, these
findings support the notion that there are underlying global mitochondrial impairments in
FRDA; however, some cell types are less susceptible than others to their
pathophysiological effects.186,201 An ex vivo challenge, such as applied oxidative stress or
a galactose-only environment to drive OXPHOS-dependent ATP production, may be
required to reveal the phenotype in these tissues.
It is important to note that these acyl-CoA changes are only static measurements
of metabolite levels, and do not give us any information on which pathways are
upregulated or downregulated to cause these changes. To determine the source of
increased succinyl-CoA, we used isotopic tracer analysis with [U-13C6]-glucose and [U13

C16]-palmitic acid to measure not only changes in concentrations of metabolites, but

also flux of metabolism through the citric acid cycle and β-oxidation of long-chain acylCoAs. Evidence for utility of isotopic tracer analysis as a potential biomarker for
mitochondrial dysfunction in FRDA was shown through experiments highlighting a
different form of mitochondrial impairment; rotenone-treated SH-SY5Y neuroblastoma
cells led to inhibition of biosynthesis of [U-13C6]-glucose-derived [13C]-acetyl-CoA and
[13C]-succinyl-CoA and increased [U-13C16]-palmitic acid-derived [13C]-acetyl-CoA,
suggesting that isotopic tracer analysis may be a useful marker of altered metabolism in
disease with mitochondrial dysfunction.12 To assess potential changes in mitochondrial
metabolism in FRDA, we first performed isotopomer analysis of short-chain acyl-CoAs
derived from [U-13C6]-glucose and [U-13C16]-palmitic acid in transfected HEK293 cells.
We found a significant decrease in [U-13C6]-glucose-derived succinyl-CoA and a
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significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA in frataxin
knockdowns, which may suggest that decreased glucose metabolism through the TCA
cycle may be compensated by increased fatty acid oxidation FRDA cells. Interestingly,
frataxin levels were higher in knockdown cells grown in the added [U-13C16]-palmitic
acid label compared to cells grown in 1 mg/mL [U-13C6]-glucose and unlabeled
knockdowns. As fatty acid metabolism appears to be upregulated in frataxin-deficient
cells, it is possible that these cells benefit from exogenous palmitic acid; however, a more
likely interpretation is that palmitic acid may be interfering with the lipid-based
transfection in some manner, affecting transfection efficiency of siRNAs. Frataxin
knockdowns in the presence of unlabeled palmitic acid were not performed for these
experiments, but would provide added insight into these findings.
In platelets isolated from freshly drawn whole blood, we measured significant
decreases in [U-13C16]-palmitic acid-derived labeling of succinyl-CoA in M2 and 3HMG-CoA in M2 and M4, with a nonsignificant decrease in acetyl-CoA labeling in M2
in FRDA platelets relative to controls. These data suggest that FRDA patients may have a
decreased dependency of fatty acid oxidation or an impairment in the enzymes required
for beta-oxidation. As platelets do not have the genetic machinery to upregulate
expression of enzymes involved in fatty acid oxidation, these changes may be attributed
to impaired activity of enzymes downstream of reduced frataxin. In fact, fatty acid
oxidation is dependent on ISC-containing enzymes, which may be affected in FRDA
patients. The first step of fatty oxidation involves acyl-CoA dehydrogenase, which
catalyzes the formation of a trans-double bond between C2 and C3 of an acyl-CoA
129

substrate. Acyl-CoA dehydrogenase requires flavin adenine dinucleotide (FAD) as a
cofactor in the reaction, which is reduced to FADH2. Acyl-CoA dehydrogenase is then
reoxidized through a reduction of electron-transfer flavoprotein (ETF), which is itself
reoxidized by ETF:ubiquinone oxidoreductase, an ISC-containing enzyme, which may
account for the apparent decreased fatty acid oxidation in FRDA patients.
ETF:ubiquinone oxidoreductase also links fatty acid oxidation to the electron transport
chain through the reduction of ubiquinone (coenzyme Q) to ubiquinol. During our
studies, we also tried extracting medium and long-chain acyl-CoA species after labeling
with [U-13C16]-palmitic acid to measure levels of a wider variety of metabolites of fatty
acid beta-oxidation; however, we were unable to clearly detect these compounds and will
need to refine the extraction process before continuing. We had measured an overall
increase in static levels of succinyl-CoA in FRDA platelets relative to control, so the
decrease in [U-13C16]-palmitic acid-derived succinyl-CoA is an interesting finding. It is
possible that platelets from FRDA patients do not rely as heavily on fatty acid
metabolism compared to controls, and compensate using other pathways that generate
succinyl-CoA as an intermediate. Labeling with [U-13C6]-glucose or [13C515N2]glutamine did not result in significant labeling of short-chain acyl-CoA species in control
or FRDA platelets (data not shown), suggesting that platelets either do not rely on
pathways involving these metabolites, or do not possess mechanisms to take up the
isotopic tracers.
In these experiments, we spiked whole blood with isotopic tracers at
concentrations compatible with normal serum levels of the unlabeled nutrient. This
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allowed us to detect significant levels of labeled acyl-CoA species without the tracers
interfering significantly with normal physiological function. However, if levels of
engodenous, unlabeled compounds are elevated (from diet, for example), then there could
be unexpected competition with the labeled tracers, dampening the amount of labeling we
are able to detect. Ideally, subjects were fasted before donation of blood for platelet
isolation to circumvent this issue, but it was not always possible. Another measure to
lessen the impact of endogenous compounds on their heavy-labeled isotopes would be to
spike the compound after platelets are pelleted and washed, instead of before; however,
preliminary experiments showed that there was no difference in percentage labeling of
acyl-CoAs when spiking tracers into samples at various stages of processing. In fact, we
opted to spike tracers into whole blood before isolating platelets, thereby omitting several
wash steps to decrease harvesting and processing artifacts and maintaining more
physiologically relevant conditions.
Finally, we also performed isotopmer analysis of short-chain acyl-CoA species in
control and patient fibroblasts. While not as rich in mitochondria as platelets, fibroblasts
represent a relatively easy to obtain source of sample material that can be subjected to
longer incubation times with isotopic tracers for optimization of labeling. We found that
culturing fibroblasts in the presence of 13C isotopic tracers for 48-72 hours was optimal
for labeling of short-chain acyl-CoA species. We found that approximately 20% of total
acetyl-CoA was labeled in M2 by [U-13C6]-glucose for both control and FRDA
fibroblasts, without any significant labeling of succinyl-CoA. There was more substantial
labeling of acetyl-CoA in M2 by [U-13C16]-palmitic acid; FRDA fibroblasts showed
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significantly higher labeling of acetyl-CoA relative to controls (45.9% vs 27.6%, p =
0.004). This follows the same trend as transfected HEK293 cells, and suggests that these
cell types are able to upregulate fatty acid oxidation in a reduced frataxin environment,
unlike platelets. The GM03665 FRDA fibroblast cell line also appears to grow much
more slowly than the control GM08402 cell line; the FRDA fibroblasts may be
upregulating metabolic pathways simply to maintain cell viability. However, we do not
see a significant difference in [U-13C6]-glucose metabolism between the control and
patient fibroblast lines when compared to transfected HEK293 cells. This could be
partially attributed to a selection for cells with higher frataxin levels and a less severe
phenotype to survive after numerous passages, resulting in an overall homogenization of
phenotype between cell lines. For example, while frataxin protein levels as measured by
Western blot and dipstick assay are reduced in the two patient lines relative to the control
line, there was much variability and the results were difficult to reproduce. Similarly, it
was reported by the Wilson lab that qRT-PCR analysis of the GM08402, GM03665, and
GM03816 fibroblasts lines revealed that expression levels of frataxin mRNA were
indistinguishable (data not shown). To circumvent the possibility that these cell lines may
no longer carry a relevant phenotype, we can use fibroblasts cultured from skin biopsies
donated by FRDA patients and healthy controls. While it takes several weeks for cells to
grow from the biopsy explants, we have already successfully cultured fibroblasts from
control and carrier skin biopsies in the lab, so we will be able to pursue this option further
if necessary.
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In summary, we have shown stable isotope dilution using SILEC internal
standards in combination with LC/MS can detect changes in acyl-CoA profiles from
surrogate tissues between FRDA patients and controls. We also show that platelets are a
plentiful source of metabolically active patient material for isotopic tracer analysis, which
may lead to advancements in diagnosis and screening of mitochondrial disorders
involving enzyme deficiencies. Primary fibroblasts or lymphocytes from FRDA patients
may also be a viable alternative to freshly isolated platelets, as they can be cultured in the
presence of isotopic tracers for longer periods of time and may show acyl-CoA labeling
with more compounds than platelets. This isotopomer analysis can be expanded to
include a multitude of different isotopic tracers for the assessment of metabolic changes
in any mitochondrial disorder, not just FRDA. For example, we can use [13C6]-leucine,
[13C6]-isoleucine, or [13C5]-valine to assess metabolism through the TCA cycle from
branched chain amino acid metabolism, or [13C515N]-glutamic acid for entry into the TCA
cycle through α-ketoglutarate, which will give us multiple ways to characterize metabolic
flux through these pathways. In the future, this methodology may potentially elucidate
downstream changes in metabolism and uncover novel characteristic biomarkers or
therapeutic strategies aimed at metabolism for FRDA and other diseases affecting
mitochondrial function.
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Figure 4.1 – Schematic of the citric acid cycle, including enzymes affected in FRDA,
measureable short-chain acyl-CoAs, and potential 13C-labeled isotropic tracers for
measurement of metabolic flux.
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Figure 4.2 – Isolation and preparation of freshly isolated human platelets for (A) static
acyl-CoA measurements and (B) isotopic tracer analysis. SILEC: stable isotope labeling
by essential nutrients in cell culture, SPE: solid phase extraction.
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Figure 4.3 – Short-chain acyl-CoA measurements in HEK293 cells transfected with
frataxin siRNA. (A) Frataxin siRNA knockdown resulted in ~80% knockdown (p <
0.005). (B) Intracellular molar ratios of acetyl-CoA:succinyl-CoA in frataxin knockdown
and control HEK293 cells. Error bars represent standard deviation (n=3).
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Figure 4.4 – Short-chain acyl-CoA measurements in freshly isolated human platelets. (A)
Frataxin levels were significantly lower in patient platelets than controls as measured by
lateral flow immunoassay. (B) There were no significant differences in total acetyl-CoA
or succinyl-CoA levels between FRDA patients and controls; however, significant
differences were seen in the molar ratios of acetyl-CoA:succinyl-CoA and succinylCoA:acetyl-CoA (C). Error bars represent standard error of the mean.
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Figure 4.5 – Isotopic tracer analysis in HEK293 cells transfected with frataxin siRNA.
(A) Frataxin siRNA knockdown resulted in significant knockdown under all three
labeling conditions. (B) We found a significant decrease in [U-13C6]-glucose-derived
acetyl-CoA (p = 0.03) and a significant increase in [U-13C6]-glucose-derived succinylCoA (p = 0.04) in HEK293 cells transfected with frataxin siRNA. (C) We found a
significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA (p = 0.02) in frataxin
knockdown HEK293 cells. Error bars represent standard deviation (n=3).
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Figure 4.6 – Isotopic tracer analysis in platelet isolated from whole blood. (A) Validation
of short-chain acyl-CoA labeling by [U-13C6]-glucose and [U-13C16]-palmitic acid in
control platelets (n=3). Neither low (1 mg/mL) nor high (4.5 mg/mL, data not shown)
concentrations of [U-13C6]-glucose resulted in significant labeling over untreated
controls, while 100µM [U-13C16]-palmitic acid labeled upwards of 25% of short-chain
CoA species. (B) Frataxin levels as measured by dipstick assay showed a significant
decrease in FRDA platelets (36.5% of control, p < 0.001). (C) There were significant
decreases in labeling of succinyl-CoA in M2 (p = 0.01) and 3-HMG-CoA in M2 (p =
0.03) and M4 (p = 0.004) in FRDA platelets relative to control. Error bars represent
standard deviation (A) or standard error of the mean (B,C).

139

Figure 4.7 – Analysis of [U-13C6]-glucose and [U-13C16]-palmitic acid labeling of acetylCoA in FRDA and control fibroblast cell lines. (A,B) A time-course study was performed
with 1 mg/mL [U-13C6]-glucose and 100µM [U-13C16]-palmitic acid in control and FRDA
fibroblasts to determine the optimal length of time for acetyl-CoA (M2) labeling with 13C
isotopic tracers. (C) We found that approximately 15% of acetyl-CoA was labeled after
growing the presence of [U-13C6]-glucose for 72 hours; however, no significant
differences in labeling were seen between control and FRDA fibroblasts. (D) We found a
significant increase in [U-13C16]-palmitic acid-derived acetyl-CoA (p = 0.005) in
GM03665 FRDA fibroblasts. Error bars represent standard deviation (n=3).
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Chapter 5: Conclusions and Future Directions
5.1 Conclusions
In this thesis, we measured biomarkers of Friedreich ataxia to assess severity and
progression of disease, response to treatment, and mitochondrial dysfunction. We first
used two different immunoassays for the measurement of frataxin protein from peripheral
tissues as a screening and potential diagnostic tool in FRDA patients. Using these
methods, we were able to bypass isolation of mitochondria and measure frataxin protein
directly from easily extracted tissue samples. We detected significant differences between
control, carrier, and FRDA patient frataxin levels from a variety of peripheral cell types,
including PBMCs, platelets, whole blood, and buccal cells. Frataxin levels correlate with
GAA1 repeat length and age of onset, which suggests frataxin measurements by dipstick
assay may be a suitable biomarker for severity of disease. Receiver operator curve
analysis revealed that frataxin measurements from both whole blood and buccal cell
extracts were useful for screening for carriers and FRDA patients, and that PPV and false
negative rate was more favorable in whole blood. Lastly, we compared the utility of
frataxin measurements by the dipstick assay in whole blood to those of an xMAP-based
Luminex assay in dried blood spots as a potential screening tool in FRDA. Both assays
show strong potential as a screening tool for identifying carriers and FRDA patients in
study populations, with the Luminex assay having slightly higher PPV and sensitivity in
dried blood spots than the dipstick assay in whole blood. The assay used in clinical
studies will depend on the context of the study, the clinical setting, and the tissues
accessible to researchers.
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We then applied the measurement of frataxin protein by lateral flow dipstick
assay in a number of clinical settings. First, we demonstrated potential diagnostic
capability of the assay in patients with unknown ataxias, including FRDA patients with
atypical genetic composition. Seven of ten atypical patients had reduced frataxin protein
levels measured in cheek swab samples. Subsequent MLPA analysis revealed a novel
heterozygous partial exon 2/3 deletion in one patient, and a heterozygous exon 5 deletion
in another; these findings expand the spectrum of known disease-causing mutations in
FRDA. We also used the dipstick assay to monitor changes in frataxin protein in response
to two pharmacological treatments: ex vivo HDAC inhibitor treatment in FRDA patient
PBMCs, and in a FRDA patient receiving MAP combined chemotherapy for treatment of
osteosarcoma. Our finding that frataxin levels appear to be unchanged over long periods
of time suggest that detected changes in measured frataxin protein in response to
treatment can largely be attributed to that treatment. Our last application of the dipstick
assay involved determining whether polymorphisms in HDAC genes would predict
frataxin protein levels. We found that a Ser46Asn SNP in SIRT6 predicted a less severe
neurological phenotype and increased frataxin levels when accounting for age, sex, and
GAA1 repeat length; however, changes in FRDA phenotype may not be strongly
influenced by frataxin levels based on our linear regression model. We have shown in
this thesis that the dipstick assay is useful in multiple clinical research settings where
frataxin protein measurements can help answer questions related to diagnosis of atypical
ataxia patients, response to pharmacological treatment, relationship to disease severity
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and progression, and how levels respond to polymorphisms in genes regulating frataxin
expression.
Finally, we utilized stable isotope dilution using SILEC-labeled CoA internal
standards and isotopic tracer analysis coupled with LC/MS to assess mitochondrial
metabolism in FRDA samples. We measured a relative decrease in baseline acetylCoA:succinyl-CoA ratios in frataxin knockdown HEK293 cells relative to scrambled
siRNA controls. Similarly, we found an increase in succinyl-CoA in platelets isolated
from FRDA patients compared to control platelets. However, these findings only
represent a snapshot of mitochondrial metabolism, so we used isotopic tracer analysis to
investigate changes in metabolic flux between FRDA and control cells. We found a
significant decrease in [U-13C6]-glucose-derived [13C]-acetyl-CoA and a significant
increase in [U-13C6]-glucose-derived [13C]-succinyl-CoA in HEK293 cells transfected
with siRNA towards frataxin relative to scrambled siRNA controls. Interestingly, we
found a significant increase in [U-13C16]-palmitic acid-derived [13C]-acetyl-CoA,
suggesting increased fatty acid oxidation in frataxin-deficient cells. We then found that
platelets isolated from controls and FRDA patients were metabolically active, and
isotopomer analysis of short-chain acyl-CoAs could be assessed using isotopic labeling
with [U-13C16]-palmitic acid in whole blood. We did not find significant labeling in
platelets using [U-13C6]-glucose or [13C515N2]-glutamine, suggesting that platelets either
do not rely on pathways involving these metabolites, or do not possess mechanisms to
take up the isotopic tracers.93 We measured significant decreases in labeling of succinylCoA in M2 (p = 0.01) and 3-HMG-CoA in M2 (p = 0.03) and M4 (p = 0.004) in FRDA
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platelets relative to control by [U-13C16]-palmitic acid, suggesting patients may have
impaired or less dependency on fatty acid metabolism relative to controls. Last, primary
fibroblast lines from the Coriell Institute were used for better control over length of time
cells were grown in the presence of heavy-labeled tracers. We found a significant amount
of labeling of acetyl-CoA by [U-13C16]-palmitic acid and [U-13C6]-glucose after 72 hours.
While we did not detect a significant difference in [U-13C6]-glucose-derived acetyl-CoA
between control and FRDA fibroblasts, we did see a significant increase in [U-13C16]palmitic acid-derived acetyl-CoA in FRDA fibroblasts relative to controls, similar to
transfected HEK293 cells. Taken together, we have shown a rearrangement in FRDA
mitochondrial metabolism through the use of stable isotope dilution with SILEC internal
standards and isotopic tracer analysis using [U-13C6]-glucose and [U-13C16]-palmitic acid.
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5.2 Future Directions
In this thesis, we have shown that both the dipstick assay and the Luminex
xMAP-based assay are potentially useful as population screening and diagnostic tools
with high PPV and a low rate of false negatives. These assays would be ideal for use in
natural history studies to systematically follow frataxin levels over time alongside of
other parameters of disease, or to measure frataxin levels in response to pharmacological
intervention. While neurological exams and other performance-based measures are
typically used to assess disease progression, they are not particularly sensitive to change,
and are subject to intersite variability. Frataxin measurements represent a more
standardized biochemical marker that shows relative stability over time in untreated
individuals, and responds to pharmacological treatment aimed at increasing frataxin
levels. While we have shown that frataxin levels may predict progression of disease as
measured by a change in FARS scores, these calculations were based on retrospective
data and operated under the assumption that frataxin levels were truly unchanging over
time periods of up to eight years. If we include frataxin measurements as part of the
routine clinical visit, we can utilize a more thorough and systematic approach to assess
correlations between frataxin levels and disease severity and progression. These data
could then be useful in helping to determine whether response to treatment correlates
with rate of progression.
In addition to use as a potential screening tool in general and clinical populations,
we have shown that the dipstick assay has applications in clinical research settings aside
from observing natural history and response to treatment. We have used dipstick assays
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as a complementary diagnostic tool in FRDA patients with atypical genetic composition
and uncovered novel heterozygous deletions in two patients, broadening the spectrum of
known disease-causing mutations. Our next goal is to understand the effect these
deletions and other point mutations may have on frataxin function, and what potential
consequences may arise in the context for treatment. We have also uncovered elevated
frataxin protein levels in select cell types of fractionated whole blood in a patient with a
start codon mutation in the frataxin gene, underlying the importance of testing in multiple
cell types for patients with suspected point mutations or deletions. We can confirm which
cell types are responsible for the elevated frataxin levels through flow cytometry, and
proceed to determine what about these mutations is responsible for the apparent
upregulation of frataxin protein. Our last application of frataxin measurements involved
determining the predictive value of SNPs in HDAC genes on frataxin expression and
disease severity. We found that a Ser46Asn polymorphism in SIRT6 predicts the severity
of neurological FRDA phenotype when controlling for age, sex, and GAA1 repeat length,
but no effects were noted on non neurological features of the disorder. We also found
that SIRT6 mutation status did not appear to predict frataxin levels, suggesting that the
effect of these polymorphisms is mediated by an effect of SIRT6 itself on
pathophysiological mechanisms downstream from frataxin deficiency. If such
mechanisms can be identified, it suggests that SIRT6-mediated processes may have
potential as molecular targets in FRDA. To date, we have only measured frataxin protein
from whole blood in 181 of 505 genotyped patients in our database, resulting in small
numbers of patients that carry the minor allele. We will collect blood samples for frataxin
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measurements from as many of the remainder of these patients as we can to reducae
variation, which may help to bring out more significant differences if any polymorphism
does predict frataxin levels. In the meantime, we can use frataxin measurements in
conjunction with other genes and mutations that may alter FRDA phenotype to determine
whether a relationship exists between the two. Even if it becomes clear that these SNPs in
SIRT genes modulate phenotype independent of frataxin, there may be mutations in other
genes that affect phenotype through frataxin levels. For example, transcription factors
including SRF and TFAP2 or the transcriptional coactivator PGC-1α may have mutations
that alter regulation of frataxin expression.45,66,76,107,123,143,156 As with SIRT6, finding
mutations in genes that predict frataxin level or disease severity will provide researchers
with novel targets for therapeutic intervention in FRDA.
While dipsticks have been developed to quantify up to four different proteins and
enzymes including frataxin, the multiplex capability of the Luminex assay allows
researchers to analyze hundreds of markers for multiple diseases or multiple biomarkers
for the same disease in a single sample. This may particularly be useful as a newborn
screening test, where one can test for FRDA and several other diseases using only a
minimal amount of blood. By diagnosing FRDA at an earlier age, we potentially increase
the chances of successfully managing the disease or slowing progression by intervening
before significant cell death has occurred. While we have only measured frataxin levels
using the Luminex assay in this thesis, we have the potential to analyze other markers of
FRDA. For example, we have evidence that markers of cardiac damage, including
cardiac troponin (CTnI) and galectin-3, are chronically elevated in FRDA patients
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(Figure A.3), which may be associated with an increased risk for myocardial
damage.52,220 However, we do not know how well these values are related to patient
clinical features including frataxin levels, risk of developing cardiomyopathy, or
progression of cardiomyopathy. With the Luminex assay, we could analyze both frataxin
and CTnI from the same sample to potentially measure markers of both neurological and
cardiac disease severity and progression.
Finally, we have laid the foundation for analysis of mitochondrial metabolism in
frataxin deficient cells relative to controls, including FRDA platelets and fibroblasts. The
primary tissues affected in FRDA – heart, spinal cord, and pancreas – are clinically
inaccessible, so we must rely on surrogate tissues to monitor their mitochondrial status.
Even though platelets and fibroblasts are clinically unaffected in FRDA, they express
reduced levels of frataxin protein and may display subclinical alterations in mitochondrial
metabolism that may provide us with some insight as to why certain frataxin-deficient
cell types are more susceptible to cell death than others in FRDA. In the future, we can
use tissues from mouse models of FRDA or iPS cells to more accurately model pathology
seen in affected tissues.108,124 While we have uncovered differences in mitochondrial
metabolism in FRDA through the use of stable isotope dilution and isotopic tracer
analysis, this methodology can be extended to analyze metabolism in a variety of other
disorders with known mitochondrial dysfunction. We can use SILEC internal standards
or isotopic tracer analysis to measure ratios of metabolites positioned upstream and
downstream of any enzyme of interest to determine relative enzyme activities amongst
the samples. This is potentially useful not only in the context of ISC-containing enzymes
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in FRDA, but for enzymes at the root of other mitochondrial disorders, as well. For
example, by measuring ratios of propionyl-CoA and methylmalonyl-CoA derived from
[13C]-labeled substrates, we could reveal a possible deficiency in propionyl-CoA
decarboxylase. Similarly, medium-chain acyl-CoA dehydrogenase deficiency could be
detected through the use of [13C]-labeled substrates in fatty acid oxidation. In the
meantime, we can correct some of the issues we had surrounding extraction and analysis
of long-chain acyl-CoA species for a more thorough analysis of fatty acid oxidation, and
begin to incorporate the use of more isotopic tracers for analysis. Although we did have
some difficulty with [U-13C6]-glucose and [13C515N2]-glutamine labeling in platelets, this
may have been a result of platelets lacking the relevant uptake mechanisms; however,
platelets do express glutamate transporters and glutamine synthetase, so we hope to use
[13C515N]-glutamic acid as another tracer to further assess metabolism downstream of
aconitase in the TCA cycle.21,160,222 We can also use [13C6]-leucine, [13C6]-isoleucine, or
[13C5]-valine as tracers to assess metabolism through the TCA cycle from branched chain
amino acid metabolism, and analyze heavy-labeled organic acids in addition to CoA
species to have a more complete characterization of metabolic flux through and around
the TCA cycle. Ideally, as we troubleshoot the nuances associated with various isotopic
tracers, we will theoretically be able to perform isotopomer analysis using a variety of
labeled compounds to analyze mitochondrial metabolism from a single blood sample in a
relatively inexpensive and efficient manner for biomarker analysis of multiple metabolic
disorders. Ultimately, novel biomarkers will provide researchers with further insight into
mechanisms of disease pathology and development of potential new treatments.
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Appendix

Figure A.1 – Dipstick assay standard curve using recombinant frataxin protein in
triplicate. (A) The assay was tested with up to 2000 pg of recombinant frataxin, and (B)
the assay remained linear through 500 pg. Error bars represent standard deviations (n=3).
mABS: milliabsorbance.
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Figure A.2 – Dipstick assay standard curves using samples collected from a
representative control in triplicate. (A) Platelets, (B) Whole Blood, and (C) Buccal Cells
all remained within the linear range of the assay over a large range of extractable protein
concentrations. Error bars represent standard deviations (n=3). mABS: milliabsorbance.
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Table A.1 – Clinical features of FRDA patients providing whole blood samples for
frataxin measurement by dipstick assay.

Table A.2 – ROC analysis data comparing two screening methods from frataxin
measurements in whole blood samples by dipstick assay. CTL: control, CR: carrier.
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Table A.3 – Clinical features of FRDA patients providing cheek swab samples for
frataxin measurement by dipstick assay.

Table A.4 - ROC analysis data comparing two screening methods from frataxin
measurements in cheek swab samples by dipstick assay. CTL: control, CR: carrier.
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Table A.5 – Spike and recovery analysis in representative control buccal cell and whole
blood samples run in triplicate. The assay demonstrated sufficient recovery of up to 100
pg of recombinant frataxin in both cell types without significant enhancement or
interference from the test sample milieu. RF: recombinant frataxin, BC: buccal cell
sample, mABS: milliabsorbance.
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Table A.6 – Lateral flow immunoassay intra- and inter-assay variation and inter-sample
variation in whole blood and cheek swab samples run in triplicate. Samples from a
representative control were collected on three different days and frataxin levels were
measured in triplicate. Intra-assay variation: variation between samples from the same
day on the same plate, Inter-assay variation: variation between plates from the same
sample, Inter-sample variation: variation between samples from the same plate, mABS:
milliabsorbance, CV: coefficient of variation, CTL: control sample.
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Table A.7 – Whole blood and cheek swap sample storage data. Mean corrected frataxin
mABS values from a current representative control were compared to samples stored at 80°C collected from the previous four years (when applicable). All samples were run in
triplicate and maintained low intra-assay CV values, but cheek swab samples showed
more variation between samples from year-to-year compared to whole blood. CV:
coefficient of variation, mABS: milliabsorbance.
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Table A.8 - Clinical features of FRDA patients providing whole blood samples for
comparisons in frataxin measurements by dipstick assay and Luminex assay.

Table A.9 - ROC analysis data comparing population screening utility in whole blood by
dipstick assay versus Luminex assay. CTL: control, CR: carrier.
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Table A.10 – Clinical information and frataxin measurements by dipstick assay in buccal
cells and whole blood from FRDA patients with point mutations. BC: buccal cell sample.
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Table A.11 – Longitudinal frataxin measurements in whole blood from a representative
FRDA patient run in triplicate (GAA1 = 454, GAA2 = 777, age of onset = 15) reveal the
mean corrected mABS values for frataxin protein measurements remain relatively
constant over time. The p-values represent results of paired t-test analyses on samples
from consecutive dates. CV: coefficient of variation, mABS: milliabsorbance.
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Table A.12 - Clinical information and frataxin measurements by dipstick assay and
Western blot in fibroblasts from the Coriell Institute.
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1

Table A.13 – Clinical information and frataxin measurements by dipstick assay in
platelets isolated from FRDA patients in the mitochondrial metabolism study.
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Figure A.3 – Galectin-3 measurements in plasma as a marker of myocardial damage from
controls, carriers, FRDA patients, and acute heart failure patients. FRDA patients have
slightly elevated galectin-3 levels compared to controls and carriers, but the increase is
not statistically significant. CHF: coronary heart failure patients.
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